Page last updated: 2024-10-30

methadone and Neoplasms

methadone has been researched along with Neoplasms in 223 studies

Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Intravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways."9.41Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature. ( Mercadante, S, 2023)
"This study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone."9.17Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. ( Lauretti, GR; Mattos, AL; Rizzo, CC; Rodrigues, SW, 2013)
"To compare the effectiveness and side effects of methadone and morphine as first-line treatment with opioids for cancer pain."9.11Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. ( Bertolino, M; Bosnjak, S; Bruera, E; Fisch, MJ; Mathias, C; Moyano, J; Palmer, JL; Rico, MA; Spruyt, O; Strasser, F; Sweeney, C; Willey, J, 2004)
"Methadone is effective for chronic cancer pain, but its early pharmacodynamic profile and effectiveness for breakthrough pain remain uncertain."9.11Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. ( Fisher, K; Hagen, NA; Stiles, C, 2004)
"Methadone is a strong opioid analgesic that has been used successfully in cancer pain management."9.11Intermittent subcutaneous methadone administration in the management of cancer pain. ( Centeno, C; Vara, F, 2005)
"This prospective study documents the use of methadone as part of an opioid rotation strategy in patients with uncontrolled pain and severe delirium admitted for terminal care to a tertiary cancer palliative care hospital."9.11Methadone in the treatment of pain and terminal delirum in advanced cancer patients. ( Comfort, C; Kogan, M; Moryl, N; Obbens, E, 2005)
"The successful use of methadone in cancer pain has been supported by numerous case reports and clinical studies."9.10Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. ( Derby, S; Fischberg, D; Kornick, C; Manfredi, PL; Moryl, N; Payne, R; Santiago-Palma, J, 2002)
"To assess the use of methadone in patients with cancer pain who fail to respond to increasing doses of other opioids or experience intolerable side-effects from them."9.09Methadone titration in opioid-resistant cancer pain. ( Gonty, N; Scholes, CF; Trotman, IF, 1999)
"In a prospective, open study, 37 advanced cancer patients in poor pain control receiving high doses of subcutaneous hydromorphone (mean daily dose: 276 +/- 163 mg) were switched to methadone by use of custom-made capsules (21 patients) or suppositories (16 patients)."9.08Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. ( Bruera, E; Fainsinger, RL; Inturrisi, C; Spachynski, K; Suarez-Almazor, M; Watanabe, S, 1995)
"Methadone is a very useful drug in cancer pain because of its low cost, lack of active metabolites, high oral availability, and the rapid onset of its analgesic effect."9.08Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. ( Caligara, M; Mercadante, S; Sapio, M; Serretta, R, 1996)
"To determine the relationship between changes in plasma methadone concentration and pharmacodynamic effects, plasma methadone profiles and pharmacodynamics (analgesia and sedation) were measured during and after the continuous infusion of methadone for 180 to 270 minutes in 15 patients with pain caused by cancer."9.06Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. ( Colburn, WA; Foley, KM; Inturrisi, CE; Max, MB; Portenoy, RK, 1990)
"Eighteen patients suffering from cancer were entered into a study of the pharmacokinetics and efficacy of methadone and morphine in pain control."9.06A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ( Cherry, DA; Cousins, MJ; Gourlay, GK, 1986)
"Methadone is a valuable opioid in the management of patients who have cancer with pain."8.98Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer. ( Costantino, RC; McPherson, AL; McPherson, ML, 2018)
"To determine the effectiveness and tolerability of methadone as an analgesic in adults and children with cancer pain."8.95Methadone for cancer pain. ( Derry, S; Nicholson, AB; Watson, GR; Wiffen, PJ, 2017)
"The proven therapeutic efficacy of methadone in cancer pain is hindered by a challenging pharmacokinetic-pharmacodynamic profile, considerable interpatient variation, and increasing concern about the complexities of dosing."8.90Therapeutic challenges in cancer pain management: a systematic review of methadone. ( Afsharimani, B; Good, P; Hardy, J; Haywood, A; Khan, S; Movva, R, 2014)
"To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain."8.89Transdermal fentanyl for cancer pain. ( Derry, S; Hadley, G; Moore, RA; Wiffen, PJ, 2013)
"To outline pharmacodynamics, pharmacokinetics, drug interactions, equianalgesic dose ratio with other opioids, dosing rules, adverse effects and methadone clinical studies in patients with cancer pain."8.85The role of methadone in cancer pain treatment--a review. ( Leppert, W, 2009)
"Methadone is an opioid used in the management of cancer pain."8.84Methadone for cancer pain. ( Nicholson, AB, 2007)
"Methadone is an opioid used in the management of cancer pain both in opioid naïve patients and in rotation from other opioids."8.82Methadone for cancer pain. ( Nicholson, AB, 2004)
" Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]."8.81The use of methadone for cancer pain. ( Bianchi, M; Ripamonti, C, 2002)
"Methadone, a synthetic opioid, has unique pharmacodynamics and pharmacokinetics, which contribute to its unique ability to relieve pain unresponsive to other potent opiates and its unique dosing and drug interactions."8.81Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. ( Davis, MP; Walsh, D, 2001)
"In recent years a better understanding of the pharmacologic and pharmacokinetic properties of methadone, including equianalgesic ratios has led to its increased use as a second line opioid for the treatment of pain in patients with cancer."8.81Methadone use in cancer patients with pain: a review. ( Bruera, E; Sweeney, C, 2002)
"Methadone is commonly considered an alternative opioid treatment for refractory cancer pain."8.12Methadone switching for refractory cancer pain. ( Ding, H; Fang, L; Gong, L; He, C; Song, Y; Sun, J; Xin, W; Zhong, L; Zhou, Q, 2022)
"Methadone is a useful option in the treatment of cancer pain."8.12Methadone rotation for cancer pain: an observational study. ( Hum, A; Tan, C; Wong, JF; Yee, CM, 2022)
"The prevalence of poisoning from methadone and prescription opioids is increasing in pediatric populations."8.02A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children. ( Farnaghi, F; Gholami, N; Hassanian-Moghaddam, H; McDonald, R; Saberi, M; Zamani, N, 2021)
"To describe the titration phase of the treatment with low-dose first-line methadone and the use of methadone for breakthrough pain."8.02First-line methadone for cancer pain: titration time analysis. ( Armesto, A; Bertolino, M; Bruera, E; Bunge, S; Dran, G; Mammana, G; Orellana, F; Peirano, G; Vega, F, 2021)
"Although methadone has the potential to improve the management of cancer pain, it has some serious problems, such as respiratory depression and QT interval prolongation."8.02Assistance of a Palliative Care Certified Nurse in the Alleviation of Refractory Cancer Pain by Switching Opioids to Oral Methadone in a Japanese Outpatient Setting. ( Matsuda, Y; Okayama, S, 2021)
"The use of methadone for cancer pain is limited by the need of expertise and close titration due to variable half-life."7.83Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit. ( Armesto, A; Bertolino, MS; Camerano, G; Dran, G; Mammana, GP; Pastrana, T; Peirano, GP; Ruggiero, R; Russo, J; Varela, G; Vega, GF; Vignaroli, E, 2016)
"Previous research has reported improved pain after adding methadone to another opioid, but did not quantify this benefit using a validated outcome measure."7.79Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. ( Bryson, J; Mak, E; Ridley, J; Wallace, E; Zimmermann, C, 2013)
"Methadone is an effective and inexpensive opioid for cancer pain treatment."7.76Methadone initiation and rotation in the outpatient setting for patients with cancer pain. ( Bruera, E; Calderon, B; de la Cruz, M; El Osta, B; Li, Z; Palmer, JL; Parsons, HA, 2010)
"We conducted a feasibility study of sublingual methadone for breakthrough cancer pain, to determine whether a larger, randomized trial was warranted, and to identify a study design that would be likely to succeed."7.76A formal feasibility study of sublingual methadone for breakthrough cancer pain. ( Biondo, PD; Brasher, PM; Eliasziw, M; Hagen, NA; Moulin, DE; Stiles, CR; Watanabe, SM, 2010)
"Racemic methadone is increasingly used to manage cancer pain."7.73Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ( Auret, K; Boyd, F; Ilett, KF; Oh, TE; Page-Sharp, M; Roger Goucke, C, 2006)
"An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain."7.71Morphine and alternative opioids in cancer pain: the EAPC recommendations. ( Casas, JR; Cherny, N; Conno, F; Hanks, GW; Hanna, M; Kalso, E; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Radbruch, L; Ripamonti, C; Sawe, J; Twycross, RG; Ventafridda, V, 2001)
"Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids."7.70Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. ( Bruera, ED; Hanson, J; Lawlor, PG; Turner, KS, 1998)
"Oral methadone is considered to be a valid opioid analgesic alternative to morphine and hydromorphone in treating cancer pain."7.70Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. ( Belzile, M; Bruera, E; De Conno, F; Groff, L; Hanson, J; Pereira, J; Ripamonti, C, 1998)
"To define the dose ratio between morphine and methadone in relation to the previous morphine dose and the number of days needed to achieve the same level of analgesia in a group of patients with advanced cancer with pain who switched from morphine to oral methadone."7.70Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? ( Brunelli, C; De Conno, F; Groff, L; Polastri, D; Ripamonti, C; Stavrakis, A, 1998)
" In the past 2 years, oral methadone has been used extensively in our institution for treating children with persistent pain from cancer, burns, or trauma who were capable of oral intake and whose pain was not relieved by nonopioid medications."7.70Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases. ( Davidson, EM; Rosen, G; Shavelson, V; Shenkman, Z; Shir, Y, 1998)
"The aims of this study were to describe the analgesia, side effects, and dosage and the causes of suspension of treatment in a large sample of advanced cancer patients with pain after treatment with oral methadone from 7 to 90 days."7.69Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. ( Brunelli, C; De Conno, F; Groff, L; Ripamonti, C; Ventafridda, V; Zecca, E, 1996)
" Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3."6.82Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. ( Garzón-Rodríguez, C; González-Barboteo, J; Llorens-Torromé, S; Porta-Sales, J; Villavicencio-Chávez, C, 2016)
"Forty-two cancer patients with pain and/or opioid side effects were assessed in this randomised trial."6.77Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. ( Dale, O; Kaasa, S; Moksnes, K; Paulsen, Ø; Rosland, JH; Spigset, O, 2012)
" After achieving adequate analgesia with regular dosing of oral methadone (T1), patient-controlled analgesia with methadone was administered for 3 days (T2)."6.68Opioid-sparing effect of diclofenac in cancer pain. ( Barresi, L; Caligara, M; Dardanoni, G; Mercadante, S; Sapio, M; Serretta, R, 1997)
"Up to 44% of patients with cancer-related pain require opioid rotation (OR) because of inadequate analgesia or side effects."6.52Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. ( McLean, S; Twomey, F, 2015)
"Methadone was used subcutaneously as an analgesic agent in 1 patient."6.47Review of cancer pain management in patients receiving maintenance methadone therapy. ( McLean, S; McQuillan, R; O'Gorman, A; Rowley, D; Ryan, K, 2011)
"Ongoing assessment, multiple approaches, and excellent communication among all care management team members are critical."6.43Difficult cases in pain management: use of methadone in a multifactorial approach. ( Coyle, N; Coyne, P; Griffie, J, 2006)
"Methadone is a unique mu opioid agonist, which also has delta receptor affinity and properties of N-methyl-D-aspartate receptor antagonism and monoamine reuptake inhibition."6.43Methadone for treatment of cancer pain. ( Bryson, J; Seccareccia, D; Tamber, A; Zimmermann, C, 2006)
"Methadone is a synthetic opioid, with mu and delta receptor activity, associated with the capacity to inhibit N-methyl-D-aspartate receptors."6.41Opioid switch to oral methadone in cancer pain. ( Body, JJ; Lossignol, DA; Mancini, I, 2000)
"Trigeminal neuralgia (TN) secondary to malignancy leads to significant distress and subsequently impacts a patient's quality of life."5.91Two Patients Experience Same-Day Analgesic Effect of Methadone on Trigeminal Neuralgia Secondary to Malignancy: A Case Report. ( Akel, R; Bromberg, H; Craig, D; Guastella, A; Haas, M, 2023)
"Methadone doses were changed according to the clinical needs to obtain the most favorable balance between analgesia and adverse effects."5.72Methadone as First-line Opioid for the Management of Cancer Pain. ( Adile, C; Bonanno, G; Casuccio, A; Ferrera, P; Mercadante, S; Pallotti, MC; Ricci, M, 2022)
" An individualized approach to dosage and route should be considered based on specific clinical circumstances."5.62Methadone for Cancer Pain in Pediatric End-of-Life Care. ( Anghelescu, DL; Habashy, C; Hall, EA; Sauer, HE, 2021)
"Methadone can cause a prolonged QTc interval that can lead to ventricular arrhythmias."5.46The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain. ( Bruera, E; Liu, D; Madden, K; Park, M, 2017)
"Intravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways."5.41Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature. ( Mercadante, S, 2023)
"Methadone is a synthetic opioid with excellent oral bioavailability, variable, but long duration of action and extremely low cost."5.29Respiratory depression in a patient receiving oral methadone for cancer pain. ( Bruera, E; Hunt, G, 1995)
"Methadone is a potent analgesic used to treat refractory cancer pain."5.24Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ( George, R; Good, P; Hardy, J; Haywood, A; Hennig, S; Khan, S; Norris, R, 2017)
"This study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone."5.17Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. ( Lauretti, GR; Mattos, AL; Rizzo, CC; Rodrigues, SW, 2013)
"Data on the treatment of breakthrough cancer pain (BTcP) in patients receiving methadone therapy are lacking."5.15The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. ( Arcuri, E; Ferrera, P; Mercadante, S, 2011)
"The SAG patients reported a trend of more pain, had significantly more dropouts and three SAEs, which indicate that the SAG strategy should not replace the 3DS when switching from high doses of morphine or oxycodone to methadone."5.15How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. ( Dale, O; Kaasa, S; Klepstad, P; Moksnes, K; Paulsen, O; Rosland, JH, 2011)
"Methadone was administered to 21 opioid-tolerant cancer patients because of pain (numerical rating scale [NRS] > 5) on morphine (ten patients), transdermal fentanyl (TF; four patients), morphine, ketamine, and TF (one patient), tramadol (one patient), pethidine (one patient), pain with drowsiness on morphine with ketamine (three patients), and pain with nausea on morphine (one patient)."5.14The role of methadone in opioid rotation-a Polish experience. ( Leppert, W, 2009)
"This study aims to evaluate the efficacy of methadone as substitute for morphine and to investigate if the addition of acetaminophen could reduce the time to attain an equianalgesic dose of methadone and/or to improve the level of pain control in oncologic patients."5.14Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. ( Cubero, DI; del Giglio, A, 2010)
"The purpose of this study was to determine the effect of initiation of methadone on QTc interval in patients with cancer pain seen at the palliative care setting."5.14The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. ( Bruera, E; de la Cruz, M; El Osta, B; Hui, D; Palmer, JL; Reddy, S; Walker, P, 2010)
"To compare the effectiveness and side effects of methadone and morphine as first-line treatment with opioids for cancer pain."5.11Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. ( Bertolino, M; Bosnjak, S; Bruera, E; Fisch, MJ; Mathias, C; Moyano, J; Palmer, JL; Rico, MA; Spruyt, O; Strasser, F; Sweeney, C; Willey, J, 2004)
"Methadone is effective for chronic cancer pain, but its early pharmacodynamic profile and effectiveness for breakthrough pain remain uncertain."5.11Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. ( Fisher, K; Hagen, NA; Stiles, C, 2004)
"Methadone is a strong opioid analgesic that has been used successfully in cancer pain management."5.11Intermittent subcutaneous methadone administration in the management of cancer pain. ( Centeno, C; Vara, F, 2005)
"This prospective study documents the use of methadone as part of an opioid rotation strategy in patients with uncontrolled pain and severe delirium admitted for terminal care to a tertiary cancer palliative care hospital."5.11Methadone in the treatment of pain and terminal delirum in advanced cancer patients. ( Comfort, C; Kogan, M; Moryl, N; Obbens, E, 2005)
"The successful use of methadone in cancer pain has been supported by numerous case reports and clinical studies."5.10Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. ( Derby, S; Fischberg, D; Kornick, C; Manfredi, PL; Moryl, N; Payne, R; Santiago-Palma, J, 2002)
"To assess the use of methadone in patients with cancer pain who fail to respond to increasing doses of other opioids or experience intolerable side-effects from them."5.09Methadone titration in opioid-resistant cancer pain. ( Gonty, N; Scholes, CF; Trotman, IF, 1999)
"Fifty-two consecutive cancer patients receiving oral morphine but with uncontrolled pain and/or moderate to severe opioid adverse effects were switched to oral methadone administered every 8 hours using different dose ratios."5.09Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. ( Boffi, R; Casuccio, A; Fulfaro, F; Gebbia, V; Groff, L; Mercadante, S; Ripamonti, C; Villari, P, 2001)
"In a prospective, open study, 37 advanced cancer patients in poor pain control receiving high doses of subcutaneous hydromorphone (mean daily dose: 276 +/- 163 mg) were switched to methadone by use of custom-made capsules (21 patients) or suppositories (16 patients)."5.08Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. ( Bruera, E; Fainsinger, RL; Inturrisi, C; Spachynski, K; Suarez-Almazor, M; Watanabe, S, 1995)
"Methadone is a very useful drug in cancer pain because of its low cost, lack of active metabolites, high oral availability, and the rapid onset of its analgesic effect."5.08Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. ( Caligara, M; Mercadante, S; Sapio, M; Serretta, R, 1996)
"To determine the relationship between changes in plasma methadone concentration and pharmacodynamic effects, plasma methadone profiles and pharmacodynamics (analgesia and sedation) were measured during and after the continuous infusion of methadone for 180 to 270 minutes in 15 patients with pain caused by cancer."5.06Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. ( Colburn, WA; Foley, KM; Inturrisi, CE; Max, MB; Portenoy, RK, 1990)
"Eighteen patients suffering from cancer were entered into a study of the pharmacokinetics and efficacy of methadone and morphine in pain control."5.06A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ( Cherry, DA; Cousins, MJ; Gourlay, GK, 1986)
"Methadone is a valuable opioid in the management of patients who have cancer with pain."4.98Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer. ( Costantino, RC; McPherson, AL; McPherson, ML, 2018)
"To determine the effectiveness and tolerability of methadone as an analgesic in adults and children with cancer pain."4.95Methadone for cancer pain. ( Derry, S; Nicholson, AB; Watson, GR; Wiffen, PJ, 2017)
"The proven therapeutic efficacy of methadone in cancer pain is hindered by a challenging pharmacokinetic-pharmacodynamic profile, considerable interpatient variation, and increasing concern about the complexities of dosing."4.90Therapeutic challenges in cancer pain management: a systematic review of methadone. ( Afsharimani, B; Good, P; Hardy, J; Haywood, A; Khan, S; Movva, R, 2014)
"To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain."4.89Transdermal fentanyl for cancer pain. ( Derry, S; Hadley, G; Moore, RA; Wiffen, PJ, 2013)
"To summarize the unique characteristics of methadone and the putative mechanisms of rapid-onset opioid formulations for breakthrough pain; to outline the principles underlying opioid rotation; and to describe elements of risk assessment in opioid therapy."4.85Clinical approaches to special issues related to opioid therapy. ( Fine, PG, 2009)
"To outline pharmacodynamics, pharmacokinetics, drug interactions, equianalgesic dose ratio with other opioids, dosing rules, adverse effects and methadone clinical studies in patients with cancer pain."4.85The role of methadone in cancer pain treatment--a review. ( Leppert, W, 2009)
"Methadone is an opioid used in the management of cancer pain."4.84Methadone for cancer pain. ( Nicholson, AB, 2007)
" Evidence presented in this review shows encouraging results following the administration of methadone, fentanyl or ketamine to patients with difficult pain problems."4.82Morphine is not the only analgesic in palliative care: literature review. ( Wootton, M, 2004)
"Methadone is an opioid used in the management of cancer pain both in opioid naïve patients and in rotation from other opioids."4.82Methadone for cancer pain. ( Nicholson, AB, 2004)
" Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]."4.81The use of methadone for cancer pain. ( Bianchi, M; Ripamonti, C, 2002)
"Methadone, a synthetic opioid, has unique pharmacodynamics and pharmacokinetics, which contribute to its unique ability to relieve pain unresponsive to other potent opiates and its unique dosing and drug interactions."4.81Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. ( Davis, MP; Walsh, D, 2001)
"In recent years a better understanding of the pharmacologic and pharmacokinetic properties of methadone, including equianalgesic ratios has led to its increased use as a second line opioid for the treatment of pain in patients with cancer."4.81Methadone use in cancer patients with pain: a review. ( Bruera, E; Sweeney, C, 2002)
"In our article ?Methadone switching for refractory cancer pain' (BMC palliative care, 2022) we explore the efficacy, safety and economics of methadone in treatment of patients with refractory cancer pain in China."4.31Reply to "A better interpretation of data regarding the opioid switching to methadone". ( Ding, H; Fang, L; Gong, L; He, C; Song, Y; Sun, J; Xin, W; Zhong, L; Zhou, Q, 2023)
"Methadone is commonly considered an alternative opioid treatment for refractory cancer pain."4.12Methadone switching for refractory cancer pain. ( Ding, H; Fang, L; Gong, L; He, C; Song, Y; Sun, J; Xin, W; Zhong, L; Zhou, Q, 2022)
"Methadone is a useful option in the treatment of cancer pain."4.12Methadone rotation for cancer pain: an observational study. ( Hum, A; Tan, C; Wong, JF; Yee, CM, 2022)
"The prevalence of poisoning from methadone and prescription opioids is increasing in pediatric populations."4.02A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children. ( Farnaghi, F; Gholami, N; Hassanian-Moghaddam, H; McDonald, R; Saberi, M; Zamani, N, 2021)
"To describe the titration phase of the treatment with low-dose first-line methadone and the use of methadone for breakthrough pain."4.02First-line methadone for cancer pain: titration time analysis. ( Armesto, A; Bertolino, M; Bruera, E; Bunge, S; Dran, G; Mammana, G; Orellana, F; Peirano, G; Vega, F, 2021)
"Although methadone has the potential to improve the management of cancer pain, it has some serious problems, such as respiratory depression and QT interval prolongation."4.02Assistance of a Palliative Care Certified Nurse in the Alleviation of Refractory Cancer Pain by Switching Opioids to Oral Methadone in a Japanese Outpatient Setting. ( Matsuda, Y; Okayama, S, 2021)
"The effect of methadone on corrected QT interval (QTc) in patients with cancer pain is not well-known."3.91Evaluation of QTc Interval Prolongation Among Patients With Cancer Using Enteral Methadone. ( Hartman, A; Kale, SS; Lehman, A; Lovell, AG; Protus, BM; Saphire, ML, 2019)
"Methadone use as a second-line agent for severe cancer-related pain is increasing in the field of hospice and palliative care."3.85Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report. ( Hartwig, KN; Hoff, AM; Rosielle, DA, 2017)
"The use of methadone for cancer pain is limited by the need of expertise and close titration due to variable half-life."3.83Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit. ( Armesto, A; Bertolino, MS; Camerano, G; Dran, G; Mammana, GP; Pastrana, T; Peirano, GP; Ruggiero, R; Russo, J; Varela, G; Vega, GF; Vignaroli, E, 2016)
"Methadone offers many advantages for treating cancer pain."3.83Methadone as a Coanalgesic for Palliative Care Cancer Patients. ( Courtemanche, F; Dao, D; Gagné, F; Néron, A; Tremblay, L, 2016)
"Previous research has reported improved pain after adding methadone to another opioid, but did not quantify this benefit using a validated outcome measure."3.79Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. ( Bryson, J; Mak, E; Ridley, J; Wallace, E; Zimmermann, C, 2013)
"A retrospective, systematic chart review of levo-methadone conversions for the treatment of pain in inpatient palliative care was performed."3.78Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone. ( Gaertner, J; Klein, C; Nauck, F; Ostgathe, C; Sabatowski, R; Van Aaaken, A; Voltz, R, 2012)
"Switching to methadone from different opioids, using an initial fixed ratio followed by a flexible dosing, according to the clinical need, is highly effective and safe when performed in an acute pain relief and palliative care unit."3.78Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. ( Mercadante, S, 2012)
"A case of severe constipation is described in a 75-year- old cancer patient receiving methadone for pain."3.77Neostigmine for the treatment of gastrointestinal atony: a report of one case. ( Papa, P; Turconi, L, 2011)
"Methadone is an effective and inexpensive opioid for cancer pain treatment."3.76Methadone initiation and rotation in the outpatient setting for patients with cancer pain. ( Bruera, E; Calderon, B; de la Cruz, M; El Osta, B; Li, Z; Palmer, JL; Parsons, HA, 2010)
"We conducted a feasibility study of sublingual methadone for breakthrough cancer pain, to determine whether a larger, randomized trial was warranted, and to identify a study design that would be likely to succeed."3.76A formal feasibility study of sublingual methadone for breakthrough cancer pain. ( Biondo, PD; Brasher, PM; Eliasziw, M; Hagen, NA; Moulin, DE; Stiles, CR; Watanabe, SM, 2010)
"Racemic methadone is increasingly used to manage cancer pain."3.73Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ( Auret, K; Boyd, F; Ilett, KF; Oh, TE; Page-Sharp, M; Roger Goucke, C, 2006)
"Methadone has been used as an alternative strong opioid to morphine in the management of cancer pain."3.72An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. ( Ma, HM; Ng, DK; Sham, MM; Tse, DM, 2003)
"An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain."3.71Morphine and alternative opioids in cancer pain: the EAPC recommendations. ( Casas, JR; Cherny, N; Conno, F; Hanks, GW; Hanna, M; Kalso, E; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Radbruch, L; Ripamonti, C; Sawe, J; Twycross, RG; Ventafridda, V, 2001)
"Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids."3.70Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. ( Bruera, ED; Hanson, J; Lawlor, PG; Turner, KS, 1998)
"Oral methadone is considered to be a valid opioid analgesic alternative to morphine and hydromorphone in treating cancer pain."3.70Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. ( Belzile, M; Bruera, E; De Conno, F; Groff, L; Hanson, J; Pereira, J; Ripamonti, C, 1998)
"To define the dose ratio between morphine and methadone in relation to the previous morphine dose and the number of days needed to achieve the same level of analgesia in a group of patients with advanced cancer with pain who switched from morphine to oral methadone."3.70Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? ( Brunelli, C; De Conno, F; Groff, L; Polastri, D; Ripamonti, C; Stavrakis, A, 1998)
" In the past 2 years, oral methadone has been used extensively in our institution for treating children with persistent pain from cancer, burns, or trauma who were capable of oral intake and whose pain was not relieved by nonopioid medications."3.70Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases. ( Davidson, EM; Rosen, G; Shavelson, V; Shenkman, Z; Shir, Y, 1998)
"Hyperalgesia and allodynia in 4 cancer patients treated with morphine disappeared after discontinuing or substituting morphine with other opioid agonists."3.69Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. ( Jensen, NH; Jensen, TS; Sjøgren, P, 1994)
"The aims of this study were to describe the analgesia, side effects, and dosage and the causes of suspension of treatment in a large sample of advanced cancer patients with pain after treatment with oral methadone from 7 to 90 days."3.69Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. ( Brunelli, C; De Conno, F; Groff, L; Ripamonti, C; Ventafridda, V; Zecca, E, 1996)
"A sample if 41 patients with cancer-related pain in palliative setting were included."3.01A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain. ( Duarte, FCN; Ferraro, LHDC; Ferreira, A; Sakata, RK, 2021)
" Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3."2.82Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. ( Garzón-Rodríguez, C; González-Barboteo, J; Llorens-Torromé, S; Porta-Sales, J; Villavicencio-Chávez, C, 2016)
"Forty-two cancer patients with pain and/or opioid side effects were assessed in this randomised trial."2.77Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. ( Dale, O; Kaasa, S; Moksnes, K; Paulsen, Ø; Rosland, JH; Spigset, O, 2012)
"Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise."2.73Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. ( Aielli, F; Casuccio, A; Ferrera, P; Ficorella, C; Fulfaro, F; Gebbia, V; Mangione, S; Mercadante, S; Porzio, G; Riina, S; Verna, L; Villari, P, 2008)
" A scoping review was performed to evaluate whether existing literature on methadone bioavailability in human subjects support the current recommendation that an equivalent enteral dose is twice the intravenous dose."2.72Methadone bioavailability and dose conversion implications with intravenous and enteral administration: A scoping review. ( Craig, WY; Fraser, GL; Kemp, HD; Liu, J; McKelvy, DJ; Nichols, SD; Riker, RR; Smith, KE, 2021)
"Methadone was initiated 8-24 hours after fentanyl withdrawal, depending on the patient's previous opioid doses (from < 100 microg per hour to > 300 microg per hour)."2.71Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. ( Benítez-Rosario, MA; Feria, M; Martín-Ortega, JJ; Martínez-Castillo, LP; Salinas-Martín, A, 2004)
"Methadone is a drug of indisputable value in the treatment of cancer pain, and an unbalanced focus on the risks of inappropriate use rather than the benefits should not compromise the use of a relevant alternative to morphine in the management of cancer pain."2.69Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. ( Agnello, A; Barresi, L; Calderone, L; Casuccio, A; Mercadante, S; Serretta, R, 1998)
" After achieving adequate analgesia with regular dosing of oral methadone (T1), patient-controlled analgesia with methadone was administered for 3 days (T2)."2.68Opioid-sparing effect of diclofenac in cancer pain. ( Barresi, L; Caligara, M; Dardanoni, G; Mercadante, S; Sapio, M; Serretta, R, 1997)
" Dosing intervals, pain intensity assessments and toxicity were evaluated."2.66Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. ( Enterline, J; Green, L; Grochow, L; Grossman, S; Sheidler, V, 1989)
"Thirty-two postoperative cancer patients received deltoid and gluteal injections of morphine, 8 and 16 mg, within a double-blind, twin crossover design."2.65Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine. ( Grabinski, PY; Houde, RW; Kaiko, RF; Rogers, AG, 1983)
"Methadone is an opioid that is only approved for replacement therapy in Austria."2.58Methadone as anticancer treatment: hype, hope, or hazard? : A series of case reports and a short review of the current literature and recommendations of the societies. ( Hackner, K; Kreye, G; Masel, EK; Nauck, F; Stich, B, 2018)
"Its administration against cancer pain is, however, tenable, albeit restricted to certain clinical situations."2.58Methadone against cancer: Lost in translation. ( Mikus, G; Theile, D, 2018)
"Methadone is a synthetic opioid with unique pharmacodynamic and pharmacokinetic properties."2.58Methadone for Pain Management in Children with Cancer. ( Anghelescu, DL; Habashy, C; Hall, EA; Springer, E, 2018)
"Refractory cancer pain that does not respond to standard opioid and/or co-analgesic therapy occurs in 10-20 % of patients."2.52Pharmacological options for the management of refractory cancer pain-what is the evidence? ( Afsharimani, B; Good, P; Hardy, J; Kindl, K, 2015)
"Up to 44% of patients with cancer-related pain require opioid rotation (OR) because of inadequate analgesia or side effects."2.52Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. ( McLean, S; Twomey, F, 2015)
"Methadone was used subcutaneously as an analgesic agent in 1 patient."2.47Review of cancer pain management in patients receiving maintenance methadone therapy. ( McLean, S; McQuillan, R; O'Gorman, A; Rowley, D; Ryan, K, 2011)
"Up to 80% of people with cancer experience pain at some time during their illness, and most will need opioid analgesics."2.44Opioids in people with cancer-related pain. ( Quigley, C, 2008)
" This article reviews the World Health Organization recommendations for analgesic therapy in this setting, as well as guidelines for opioid therapy in patients with renal failure or hepatic failure, assessment of pain, dosing strategies in both acute and chronic pain, management of opioid overdose, pain associated with dose-limiting side effects, and pain in the actively dying."2.44Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know. ( Davis, MP; Gamier, P; Lasheen, W, 2007)
"Ongoing assessment, multiple approaches, and excellent communication among all care management team members are critical."2.43Difficult cases in pain management: use of methadone in a multifactorial approach. ( Coyle, N; Coyne, P; Griffie, J, 2006)
"Methadone is a unique mu opioid agonist, which also has delta receptor affinity and properties of N-methyl-D-aspartate receptor antagonism and monoamine reuptake inhibition."2.43Methadone for treatment of cancer pain. ( Bryson, J; Seccareccia, D; Tamber, A; Zimmermann, C, 2006)
" Regular pain assessments combined with appropriate analgesic administration at regular dosing intervals, adjunctive drug therapy for control of adverse effects and associated symptoms, and nonpharmacological interventions are recommended."2.42Cancer pain management in children. ( Mercadante, S, 2004)
"Methadone is a synthetic opioid, with mu and delta receptor activity, associated with the capacity to inhibit N-methyl-D-aspartate receptors."2.41Opioid switch to oral methadone in cancer pain. ( Body, JJ; Lossignol, DA; Mancini, I, 2000)
"Methadone is a potent synthetic opioid analgesic best known in Australia as maintenance therapy for narcotic addicts."2.41The rediscovery of methadone for cancer pain management. ( Ayonrinde, OT; Bridge, DT, 2000)
" When initiating treatment, controlled-release preparations of opioids are generally favoured, and are combined with immediate release morphine to prevent or treat 'breakthrough' pain and to enable the optimum opioid dosage to be calculated."2.41[Treatment of pain in cancer with systemically administered opioids]. ( de Wit, R; Enting, RH; Lieverse, PJ; Smitt, PA; van der Rijt, CC; Wilms, EB, 2001)
"Methadone is a synthetic opioid agonist considered a second choice drug in the management of cancer pain."2.40An update on the clinical use of methadone for cancer pain. ( Bruera, E; Ripamonti, C; Zecca, E, 1997)
"Tramadol is a centrally acting analgesic drug; it has an agonist effect on mu 1 receptors of opioids and acts also by inhibiting the re-uptake of noradrenaline and serotonine which activates descending monoaminergic inhibitory pathways."2.40[Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997)
" Issues to be explored include a potential role in treating patients who have poorly responsive pain syndromes, such as neuropathic pain, or who develop a rapid tolerance to other opioids; the possibility of extending dosing intervals to every 12 or 24 hours; and its possible use as a first-line opioid."2.40Role of methadone in the management of pain in cancer patients. ( Bruera, E; Neumann, CM, 1999)
"When pain is relieved inadequately by opioid analgesics given in a dose that causes intolerable side effects despite routine measures to control them, treatment with the same opioid by an alternative route or with an alternative opioid administered by the same route should be considered."2.40Opioid rotation for cancer pain: rationale and clinical aspects. ( Mercadante, S, 1999)
"Methadone is a synthetic opiate receptor agonist that has been available for more than 40 years."2.38Methadone in the management of cancer pain: a review. ( Bruera, E; Fainsinger, R; Schoeller, T, 1993)
"Trigeminal neuralgia (TN) secondary to malignancy leads to significant distress and subsequently impacts a patient's quality of life."1.91Two Patients Experience Same-Day Analgesic Effect of Methadone on Trigeminal Neuralgia Secondary to Malignancy: A Case Report. ( Akel, R; Bromberg, H; Craig, D; Guastella, A; Haas, M, 2023)
"Methadone doses were changed according to the clinical needs to obtain the most favorable balance between analgesia and adverse effects."1.72Methadone as First-line Opioid for the Management of Cancer Pain. ( Adile, C; Bonanno, G; Casuccio, A; Ferrera, P; Mercadante, S; Pallotti, MC; Ricci, M, 2022)
"Opioid misuse and opioid use disorder (OUD) are important comorbidities in people with advanced cancer and cancer-related pain, but there is a lack of consensus on treatment."1.72Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder. ( Arnold, R; Bulls, H; Dao, E; Fitzgerald Jones, K; Kapo, J; Khodyakov, D; Liebschutz, J; Meier, D; Merlin, J; Paice, J; Ritchie, C, 2022)
" There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians."1.72Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life. ( Albury, CL; George, R; Good, P; Griffiths, LR; Hardy, J; Haupt, LM; Haywood, A; Ozberk, D; Sutherland, HG; Yu, C; Zunk, M, 2022)
"MR for CIBP may result in reduction in pain intensity, when other opioids are ineffective or intolerable, with patients requiring reduced overall dosing of their long-acting opioid and frequency of breakthrough opioid use."1.62The role of methadone in cancer-induced bone pain: a retrospective cohort study. ( Al-Rubaie, Z; Key, S; Kwok, J; Michael, N; Sulistio, M; Wojnar, R, 2021)
" An individualized approach to dosage and route should be considered based on specific clinical circumstances."1.62Methadone for Cancer Pain in Pediatric End-of-Life Care. ( Anghelescu, DL; Habashy, C; Hall, EA; Sauer, HE, 2021)
"All study participants reported cancer pain with neuropathic components; most had mixed pain syndromes comprising nociceptive and neuropathic components."1.62Combination therapy with methadone and duloxetine for cancer-related pain: a retrospective study. ( Abdullaziz, S; Curry, ZA; Dang, MC; Del Fabbro, EG; Sima, AP, 2021)
"Opioids are the first-line treatment for cancer pain."1.62Antinociceptive synergism upon the joint use of methadone and Phα1β in a model of cancer-related pain in C57BL/6J mice. ( Aoki, CT; Castro Junior, CJ; Delgado, MA; Ferreira, J; Ferreira, LA; Gomez, MV; Mendes, MP; Moura, RA; Rezende, MJ; Santos, DC, 2021)
"Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach."1.51Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. ( Anghelescu, DL; Tesney, JM, 2019)
"Methadone can cause a prolonged QTc interval that can lead to ventricular arrhythmias."1.46The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain. ( Bruera, E; Liu, D; Madden, K; Park, M, 2017)
"Methadone has been associated with lower overall survival (OS) in patients with chronic pain."1.46Overall Survival among Cancer Patients Undergoing Opioid Rotation to Methadone Compared to Other Opioids. ( Bruera, E; de la Cruz, M; Liu, D; Reddy, A; Schuler, US; Wu, J; Yennurajalingam, S, 2017)
"IV-PCA provided timely, safe and useful analgesia for patients with severe breakthrough pain and may be useful to help titration of opioids, weaning to oral analgesia and to decide for interventional procedures."1.40Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. ( Ashmawi, HA; Cascudo, GM; de Santana Neto, J; Guimaraes, GM; Neto, JO; Sousa, AM, 2014)
"Methadone was discontinued in one patient on D7 because it was deemed ineffective and for 8 patients, who were unable to take oral drugs, it was discontinued after D14."1.39Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. ( Bruera, E; Ciais, JF; Filbet, M; Ledoux, M; Rhondali, W; Tremellat, F, 2013)
"This study explored cancer incidence rates in a large cohort of Israeli (Jewish and Arab) opioid-dependent individuals receiving methadone maintenance treatment (MMT), and how the incidences vary by ethnicity and sex."1.37Methadone maintenance and cancer risk: an Israeli case registry study. ( Barchana, M; Grinshpoon, A; Lipshitz, I; Ponizovsky, AM; Rosca, P; Weizman, A, 2011)
"This paper reports two cases of myoclonus with high-dose parenteral methadone in patients with cancer under hospice care."1.35Myoclonus associated with high-dose parenteral methadone. ( Ito, S; Liao, S, 2008)
"Pain is an important and often under-treated symptom of life-threatening illness."1.35[Analgesics and palliative care]. ( Mathieu, N; Tuna, T, 2008)
"Methadone (ME) is a highly effective opioid agonist used for difficult pain syndromes."1.35Switching from methadone to a different opioid: what is the equianalgesic dose ratio? ( Bruera, E; Hanohano, J; Kaur, G; Munsell, M; Palla, S; Pei, BL; Walker, PW; Zhang, K, 2008)
"7), which approximates the bioavailability of the drug administered orally."1.35Conversion from parenteral to oral methadone. ( Gómez-Batiste, X; González-Barboteo, J; Porta-Sales, J; Sánchez, D; Tuca, A, 2008)
"We analyzed 54 cancer patients undergoing opioid rotation to clarify those factors that influenced the morphine/methadone dose ratio (MMEDR) at Day 10 after the switch."1.35Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. ( Aguirre-Jaime, A; Benítez-Rosario, MA; Feria, M; Pérez-Méndez, L; Salinas-Martín, A, 2009)
"Cancer pain is common, occurring in up to 60% of patients and opioid conversion may be required for effective pain management."1.35Inconsistencies in opioid equianalgesic ratios: clinical and research implications. ( Kutner, JS; Linnebur, SA; O'Bryant, CL; Yamashita, TE, 2008)
"Methadone was used for a total of 925 patient-days."1.35Methadone analgesia for children with advanced cancer. ( Davies, D; DeVlaming, D; Haines, C, 2008)
"Fentanyl patches were removed and the first of three daily doses of methadone was started concurrently."1.34Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ( Casuccio, A; Ferrera, P; Gambaro, V; Mercadante, S; Villari, P, 2007)
"Methadone is a synthetic opioid agonist and N-methyl-D-aspartate (NMDA) receptor antagonist that is being increasingly used in pain management, particularly for pain that is resistant to conventional opioids."1.33Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? ( Booth, CM; Cottrell, W; Seccareccia, D; Zimmermann, C, 2005)
"Methadone daily dosage was also analyzed during this study."1.32Methadone and the hospice patient: prescribing trends in the home-care setting. ( Alt, CJ; Gallagher, R; Knowlton, CH; McMath, JA; Weschules, DJ, 2003)
" For this reason, methadone is often viewed as a second line opioid, after other opioids with a more predictable dose-response have been tried."1.31Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. ( Cheville, AL; Gonzales, GR; Kornick, C; Manfredi, PL; Payne, R, 2001)
" Various strategies have been proposed to estimate safe and effective starting doses of methadone when rotating from morphine and hydromorphone; however, there are no guidelines for estimating safe and effective starting doses of methadone when rotating from fentanyl."1.31Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. ( Fischberg, DJ; Khojainova, N; Kornick, C; Manfredi, P; Payne, R; Primavera, LH; Santiago-Palma, J, 2001)
"To assess the effect of opioid substitution (substituting one member of the opioid class for another) on the incidence and severity of adverse effects in palliative care patients who experience unacceptable, refractory adverse effects when taking an opioid drug."1.30Opioid substitution to reduce adverse effects in cancer pain management. ( Ashby, MA; Jackson, KA; Martin, P, 1999)
"Methadone dose was significantly higher in patients who had lower preswitching doses of morphine and vice versa."1.30Rapid switching from morphine to methadone in cancer patients with poor response to morphine. ( Calderone, L; Casuccio, A; Mercadante, S, 1999)
"Methadone can be an effective drug for cancer pain but it can also be difficult to use safely."1.30Methadone: outpatient titration and monitoring strategies in cancer patients. ( Hagen, NA; Wasylenko, E, 1999)
"Dipipanone elixir was formulated 10 mg/5 ml, in single strength chloroform water."1.29Experience with dipipanone elixir in the management of cancer related pain--case study. ( Ahmedzai, S; Faull, C; McKechnie, E; Riley, J, 1994)
"Methadone is a synthetic opioid with excellent oral bioavailability, variable, but long duration of action and extremely low cost."1.29Respiratory depression in a patient receiving oral methadone for cancer pain. ( Bruera, E; Hunt, G, 1995)
"Methadone is a potent opioid analgesic that demonstrates incomplete cross-tolerance with other mu-opioid receptor agonist analgesics."1.29Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. ( Crews, JC; Denson, DD; Sweeney, NJ, 1993)
"To study the incidence of AIDS-defining and non-AIDS-defining malignancies in injecting drug users with and without HIV infection in a methadone maintenance treatment program (MMTP)."1.28Population-based study of malignancies and HIV infection among injecting drug users in a New York City methadone treatment program, 1985-1991. ( Budner, NS; Gachupin-Garcia, A; Selwyn, PA, 1992)
"Seventy cancer patients suffering from visceral or somatic pain received continuous epidural methadone (EM) analgesia."1.28Continuous epidural methadone treatment for cancer pain. ( Kaufman, B; Magora, F; Shapira, SS; Shenkman, Z; Shir, Y, 1991)
"Morphine was used in 36 CIs, methadone in four, hydromorphone in four, oxymorphone in one, and levorphanol in one."1.27I.v. infusion of opioids for cancer pain: clinical review and guidelines for use. ( Foley, KM; Inturrisi, CE; Moulin, DE; Portenoy, RK; Rogers, A, 1986)
"Neither the type nor incidence of neoplasia was drug related but a few nonneoplastic lesions may have been."1.27In vivo carcinogenesis assay of DL-methadone.HCl in rodents. ( Fleischman, RW; Rosenkrantz, H, 1988)
"The long half-life and wide inter-patient variability in clearance of methadone make this drug difficult to use optimally."1.27Estimation of methadone clearance: application in the management of cancer pain. ( Cherry, DA; Cousins, MJ; Gourlay, GK; Plummer, JL, 1988)
" As expected, the dosage intervals increased gradually over the first few days of treatment, the daily dose decreasing from 30-80 mg on the first day to 10-40 mg at the end of the week."1.26Patient-controlled dose regimen of methadone for chronic cancer pain. ( Anggård, E; Ginman, C; Hansen, J; Hartvig, P; Jakobsson, PA; Nilsson, MI; Rane, A; Säwe, J, 1981)
" Rapid and continuous pain relief without serious side-effects was achieved by "ad libitum" dosage in the first 3-5 days."1.26Clinical evaluation of oral methadone in treatment of cancer pain. ( Anggård, E; Ginman, C; Hansen, J; Hartvig, P; Jakobsson, PA; Nilsson, MI; Rane, A; Säwe, J, 1982)
"Methadone is an effective analgesic whose pharmacokinetics must be appreciated in order for it to be used safely and effectively."1.26Important clinical pharmacologic considerations in the use of methadone in cancer patients. ( Ettinger, DS; Trump, DL; Vitale, PJ, 1979)

Research

Studies (223)

TimeframeStudies, this research(%)All Research%
pre-199039 (17.49)18.7374
1990's41 (18.39)18.2507
2000's60 (26.91)29.6817
2010's53 (23.77)24.3611
2020's30 (13.45)2.80

Authors

AuthorsStudies
Irwin, MN1
Ellingrod, VL1
Smith, MA1
Takemura, M1
Niki, K1
Okamoto, Y1
Matsuda, Y2
Omae, T1
Takagi, T1
Ueda, M1
Treillet, E1
Giet, O1
Picard, S1
Laurent, S1
Seresse, L1
Ozberk, D2
Haywood, A4
Sutherland, HG2
Yu, C2
Albury, CL2
Zunk, M2
George, R3
Good, P5
Griffiths, LR2
Hardy, J5
Haupt, LM2
Mercadante, S27
Adile, C5
Ferrera, P9
Pallotti, MC1
Ricci, M1
Bonanno, G1
Casuccio, A14
Fitzgerald Jones, K1
Khodyakov, D1
Arnold, R1
Bulls, H1
Dao, E1
Kapo, J1
Meier, D2
Paice, J1
Liebschutz, J1
Ritchie, C1
Merlin, J2
Ding, H2
Song, Y3
Xin, W2
Sun, J4
Zhong, L2
Zhou, Q3
He, C4
Gong, L2
Fang, L2
Grassi, Y1
Cascio, AL2
Bromberg, H1
Guastella, A1
Haas, M1
Akel, R1
Craig, D1
Dräger, DL1
Jones, KF1
Joudrey, P1
Meghani, S1
Fürst, P1
Lundström, S1
Klepstad, P2
Strang, P1
David, F1
Villari, P7
Spedale, VM1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J5
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z3
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J2
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Tan, C1
Wong, JF1
Yee, CM1
Hum, A2
Sulistio, M2
Wojnar, R1
Key, S1
Kwok, J1
Al-Rubaie, Z1
Michael, N1
Hall, EA2
Sauer, HE1
Habashy, C2
Anghelescu, DL3
Gholami, N1
Farnaghi, F1
Saberi, M1
Zamani, N1
McDonald, R1
Hassanian-Moghaddam, H1
Curry, ZA1
Dang, MC1
Sima, AP1
Abdullaziz, S1
Del Fabbro, EG1
Smith, KE1
Riker, RR1
Craig, WY1
McKelvy, DJ1
Kemp, HD1
Nichols, SD1
Fraser, GL1
Mammana, G1
Bertolino, M2
Bruera, E24
Orellana, F1
Vega, F1
Peirano, G1
Bunge, S1
Armesto, A2
Dran, G2
Ferreira, LA1
Aoki, CT1
Santos, DC1
Rezende, MJ1
Mendes, MP1
Moura, RA1
Delgado, MA1
Ferreira, J1
Gomez, MV1
Castro Junior, CJ1
Duarte, FCN1
Ferraro, LHDC1
Ferreira, A1
Sakata, RK1
Okayama, S1
Madden, K1
Park, M1
Liu, D2
Hoff, AM1
Hartwig, KN1
Rosielle, DA1
van den Beuken-van Everdingen, MHJ1
van Kuijk, SMJ1
Joosten, EA1
Hennig, S1
Khan, S2
Norris, R1
Aiyer, R1
Gulati, A1
Gungor, S1
Bhatia, A1
Mehta, N1
Kreye, G1
Masel, EK1
Hackner, K1
Stich, B1
Nauck, F2
Theile, D1
Mikus, G1
McPherson, ML1
Costantino, RC1
McPherson, AL1
Springer, E1
Picco Brunetto, AG1
Lovell, AG1
Protus, BM1
Saphire, ML1
Kale, SS1
Lehman, A1
Hartman, A1
Tesney, JM1
Piccininni, JA1
Killinger, JS1
Hammad, HT1
Gerber, LM1
Dayton, JD1
Gregg, JL1
Prestia, G1
Hadley, G1
Derry, S2
Moore, RA1
Wiffen, PJ2
Rhondali, W1
Tremellat, F1
Ledoux, M1
Ciais, JF1
Filbet, M1
Sousa, AM1
de Santana Neto, J1
Guimaraes, GM1
Cascudo, GM1
Neto, JO1
Ashmawi, HA1
Didwaniya, N1
Reddy, A2
Gottumukkala, RS1
Afsharimani, B2
Movva, R1
Rasmussen, VF1
Lundberg, V1
Jespersen, TW1
Hasle, H1
Kindl, K1
McLean, S2
Twomey, F1
Peirano, GP1
Mammana, GP1
Bertolino, MS1
Pastrana, T1
Vega, GF1
Russo, J1
Varela, G1
Vignaroli, E1
Ruggiero, R1
Camerano, G1
Porta-Sales, J2
Garzón-Rodríguez, C1
Villavicencio-Chávez, C1
Llorens-Torromé, S1
González-Barboteo, J3
Courtemanche, F1
Dao, D1
Gagné, F1
Tremblay, L1
Néron, A1
Ruan, X1
Luo, JJ1
Kaye, AD1
Schuler, US1
de la Cruz, M3
Yennurajalingam, S2
Hofbauer, H1
Schenk, M1
Kieselbach, K1
Wirz, S1
Nicholson, AB3
Watson, GR1
Juba, KM1
Khadem, TM1
Hutchinson, DJ1
Brown, JE1
Bond, BS1
Prommer, EE2
Ito, S1
Liao, S1
Mathieu, N1
Tuna, T1
Walker, PW1
Palla, S1
Pei, BL1
Kaur, G1
Zhang, K1
Hanohano, J1
Munsell, M1
Sánchez, D1
Tuca, A1
Gómez-Batiste, X2
Leppert, W2
Benítez-Rosario, MA2
Salinas-Martín, A2
Aguirre-Jaime, A1
Pérez-Méndez, L1
Feria, M2
Cubero, DI1
del Giglio, A1
Quigley, C1
Fine, PG1
Reddy, S2
Hui, D1
El Osta, B2
Walker, P1
Palmer, JL3
Parsons, HA1
Calderon, B1
Portenoy, RK3
Heppe, DB1
Haigney, MC1
Krantz, MJ1
Hagen, NA4
Moulin, DE2
Brasher, PM1
Biondo, PD1
Eliasziw, M1
Watanabe, SM1
Stiles, CR1
Trelis-Navarro, J1
Tuca-Rodríguez, A1
Rowley, D1
O'Gorman, A1
Ryan, K1
McQuillan, R1
Arcuri, E1
Papa, P1
Turconi, L1
Grinshpoon, A1
Barchana, M1
Lipshitz, I1
Rosca, P1
Weizman, A1
Ponizovsky, AM1
Cherny, N2
Moksnes, K2
Dale, O2
Rosland, JH2
Paulsen, O1
Kaasa, S2
O'Bryant, CL1
Linnebur, SA1
Yamashita, TE1
Kutner, JS1
Ostgathe, C1
Voltz, R1
Van Aaaken, A1
Klein, C1
Sabatowski, R2
Gaertner, J1
Paulsen, Ø1
Spigset, O1
Lauretti, GR1
Rizzo, CC1
Mattos, AL1
Rodrigues, SW1
Jackson, K1
Wallace, E1
Ridley, J1
Bryson, J2
Mak, E1
Zimmermann, C3
Ripamonti, C11
Bianchi, M5
Miles, J1
Breitfeld, C1
Eikermann, M1
Kienbaum, P1
Peters, J1
Fulfaro, F3
Gebbia, V3
Tse, DM1
Sham, MM1
Ng, DK1
Ma, HM1
Weschules, DJ1
McMath, JA1
Gallagher, R1
Alt, CJ1
Knowlton, CH1
DUNDEE, JW1
Bosnjak, S1
Rico, MA1
Moyano, J1
Sweeney, C2
Strasser, F1
Willey, J1
Mathias, C1
Spruyt, O1
Fisch, MJ1
Wootton, M1
Fisch, M1
Martínez-Castillo, LP1
Martín-Ortega, JJ1
Fisher, K2
Stiles, C2
Braiteh, F1
Centeno, C1
Vara, F1
Seccareccia, D2
Booth, CM1
Cottrell, W1
Griffie, J1
Coyne, P1
Coyle, N1
Auret, K1
Roger Goucke, C1
Ilett, KF1
Page-Sharp, M1
Boyd, F1
Oh, TE1
Moryl, N2
Kogan, M1
Comfort, C1
Obbens, E1
Tamber, A1
Gambaro, V1
Davis, MP2
Lasheen, W1
Gamier, P1
Fainsinger, RL3
Bielech, M1
Porzio, G1
Aielli, F1
Verna, L1
Ficorella, C1
Riina, S1
Mangione, S1
Davies, D1
DeVlaming, D1
Haines, C1
Reich, SD1
Säwe, J3
Hansen, J2
Ginman, C2
Hartvig, P2
Jakobsson, PA2
Nilsson, MI2
Rane, A2
Anggård, E2
Madsen, OG1
Christoffersen, I1
Philbert, A1
Paalzow, L3
Andersson, B2
Lööf, G2
Kullman, S1
Kepes, ER1
Raj, S1
Thomas, P1
Vemulapalli, K1
Ferrer-Brechner, T1
Ganz, P1
Powers, DA1
Hamilton, CW1
Roberts, KB1
Hanks, GW2
Twycross, R1
Grabinski, PY2
Kaiko, RF2
Rogers, AG1
Houde, RW2
Jaspersen, HP1
Pierce, J1
Ya Deau, RE1
Maxwell, MB2
Martinson, IM1
Nixon, S1
Geis, D1
YaDeau, R1
Nesbit, M1
Kersey, J1
Breivik, H2
Rennemo, F1
Nilsson, L1
Stenberg, P1
Portnow, JM1
Corbett, RJ1
Abramson, FP1
Faull, C1
McKechnie, E1
Riley, J1
Ahmedzai, S1
Leng, G1
Finnegan, MJ1
Hunt, G1
Crews, JC1
Sweeney, NJ1
Denson, DD1
Sjøgren, P1
Jensen, NH1
Jensen, TS1
Samuelsson, H1
Ekman, R1
Hedner, T1
Fainsinger, R2
Schoeller, T1
Watanabe, S3
Spachynski, K1
Suarez-Almazor, M1
Inturrisi, C1
O'Rourke, MA1
Shalabi, A1
Webb, S1
Belzile, M3
Kuehn, N2
Hanson, J4
Pereira, J2
De Conno, F5
Groff, L5
Brunelli, C2
Zecca, E3
Ventafridda, V4
Sapio, M2
Serretta, R3
Caligara, M2
Zacny, JP1
Dardanoni, G1
Barresi, L3
Polastri, D2
Fitzgibbon, DR1
Ready, BL1
Lawlor, PG1
Turner, KS1
Bruera, ED1
Makin, MK1
Ellershaw, JE1
River, Y1
Belgrade, M1
Foley, KM4
Stavrakis, A1
Agnello, A2
Calderone, L2
Shir, Y3
Shenkman, Z2
Shavelson, V1
Davidson, EM1
Rosen, G2
Ashby, MA1
Martin, P1
Jackson, KA1
Clavenna, A1
Scholes, CF1
Gonty, N1
Trotman, IF1
Neumann, CM1
Wasylenko, E1
Berland, D1
Oneschuk, D1
Mancini, I1
Lossignol, DA1
Body, JJ1
Shvelzon, V1
McCaffery, M1
Pasero, C1
Ayonrinde, OT1
Bridge, DT1
Manfredi, PL2
Gonzales, GR1
Cheville, AL1
Kornick, C3
Payne, R3
Conno, F1
Hanna, M1
Kalso, E1
McQuay, HJ1
Meynadier, J1
Poulain, P1
Radbruch, L2
Casas, JR1
Twycross, RG1
Walsh, D1
Boffi, R1
Enting, RH1
van der Rijt, CC1
Wilms, EB1
Lieverse, PJ1
de Wit, R1
Smitt, PA1
Clark, KJ1
Turner, K1
Dickerson, ED2
Santiago-Palma, J2
Khojainova, N1
Fischberg, DJ1
Primavera, LH1
Manfredi, P1
Kasper, SM1
Derby, S1
Fischberg, D1
Lamerton, RC1
Valentine, AS1
Steckel, S1
Weintraub, M1
Ettinger, DS1
Vitale, PJ1
Trump, DL1
Watterson, O1
Simpson, DD1
Sells, SB1
Gachupin-Garcia, A1
Selwyn, PA1
Budner, NS1
Shapira, SS1
Kaufman, B1
Magora, F1
Lang, AH1
Abbrederis, K1
Dzien, A1
Drexel, H1
Moore, M1
Thibault, R1
Spoldi, E1
Inturrisi, CE4
Max, MB2
Colburn, WA1
Li, CH1
Rogers, A1
Lo, SL1
Coleman, RR1
Grochow, L1
Sheidler, V1
Grossman, S1
Green, L1
Enterline, J1
Rosenkrantz, H2
Fleischman, RW2
Paredes, H1
Hernández, A1
San Martín, S1
Arraztoa, J1
Plummer, JL1
Gourlay, GK2
Cherry, DA2
Cousins, MJ2
Sbanotto, A1
Richlin, DM1
Jamron, LM1
Novick, NL1
Mullan, S1
Verebely, K1
Sadove, MS1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Analgesic Effect Evaluation of Methadone Associated With Morphine for Cancer Pain: Prospective Randomized Study[NCT03324815]40 participants (Anticipated)Interventional2017-03-02Recruiting
Prospective Randomized Simple Blinded Study Comparing Two Conversion Ratios From Parenteral to Oral Methadone in Patients With Cancer Pain.[NCT01836328]Phase 344 participants (Actual)Interventional2011-08-31Completed
Randomized Double-blind Controlled Study to Assess the Efficacy of Intravenous Acetaminophen Associated With Strong Opioids in the Management of Acute Pain in Adult Cancer Patients[NCT04779567]Phase 4112 participants (Actual)Interventional2019-06-10Completed
Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study[NCT00184496]Phase 342 participants (Actual)Interventional2004-08-31Completed
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects[NCT00504413]Phase 120 participants (Anticipated)Interventional2007-07-31Recruiting
Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164]Phase 30 participants (Actual)Interventional2022-09-30Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.)
Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study[NCT00525967]Phase 2/Phase 350 participants (Anticipated)Interventional2006-02-28Recruiting
A Randomized Blinded Prospective Trial Comparing Single Intraoperative Dose of Methadone Versus Placebo in Pediatric Patients Undergoing Spine Surgery.[NCT02206685]Phase 474 participants (Actual)Interventional2014-05-31Completed
Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management[NCT02335398]Phase 434 participants (Actual)Interventional2011-07-31Completed
IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction[NCT01205256]Phase 311 participants (Actual)Interventional2009-03-31Completed
Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325]Phase 324 participants (Actual)Interventional2011-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Opioid Usage

Subjects were given access to Patient-Controlled Intravenous Opioid Administration (PCA) to manage their post-operative pain. The doses of morphine were calculated at at PACU, 24 hours, 48 hours and 72 hours respectively. (NCT02206685)
Timeframe: Admission to PACU to 72 hours post-operative

,
Interventionmg/kg (Median)
PACU24 Hours48 Hours72 Hours
Control Group0.470.550.550.04
Treatment Group0.410.580.580.10

Pain Scores

The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The data reported here represents the mean difference in FLACC score by treatment group at PACU, 24 hours, 48 hours and 72 hours, respectively. (NCT02206685)
Timeframe: Admission to PACU to 72 hours post-operative

,
Interventionunits on a scale (Mean)
PACU24 Hours48 Hours72 Hours
Control Group0.650.420.360.29
Treatment Group0.530.140.240.16

Reviews

44 reviews available for methadone and Neoplasms

ArticleYear
Methadone Switching for Cancer Pain: A New Classification of Initiation Protocols, Based on a Critical Literature Review.
    Journal of palliative medicine, 2021, Volume: 24, Issue:12

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Morphine; Neoplasms; Pain; Randomized Controlled

2021
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature.
    Drugs, 2023, Volume: 83, Issue:10

    Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Chronic Pain; Humans; Methadone; Neoplasms; Pain, Posto

2023
Opioid-induced Neurotoxicity in Patients with Cancer Pain.
    Current treatment options in oncology, 2023, Volume: 24, Issue:10

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Neoplasms; Pain; Palliative Care

2023
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Methadone bioavailability and dose conversion implications with intravenous and enteral administration: A scoping review.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 07-22, Volume: 78, Issue:15

    Topics: Administration, Intravenous; Analgesics, Opioid; Biological Availability; Humans; Methadone; Neoplas

2021
Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies.
    Anesthesia and analgesia, 2018, Volume: 127, Issue:2

    Topics: Administration, Buccal; Administration, Cutaneous; Administration, Sublingual; Analgesics, Opioid; B

2018
Methadone as anticancer treatment: hype, hope, or hazard? : A series of case reports and a short review of the current literature and recommendations of the societies.
    Wiener medizinische Wochenschrift (1946), 2018, Volume: 168, Issue:7-8

    Topics: Analgesics, Opioid; Austria; Female; Germany; Humans; Methadone; Middle Aged; Morphine; Neoplasms; P

2018
Methadone against cancer: Lost in translation.
    International journal of cancer, 2018, 10-15, Volume: 143, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Methadone; Neoplasms

2018
Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer.
    Hematology/oncology clinics of North America, 2018, Volume: 32, Issue:3

    Topics: Half-Life; Humans; Inappropriate Prescribing; Methadone; Neoplasms; Pain

2018
Methadone for Pain Management in Children with Cancer.
    Paediatric drugs, 2018, Volume: 20, Issue:5

    Topics: Analgesics, Opioid; Cancer Pain; Child; Humans; Methadone; Neoplasms; Pain Management; Pain Measurem

2018
Transdermal fentanyl for cancer pain.
    The Cochrane database of systematic reviews, 2013, Oct-05, Issue:10

    Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pai

2013
Therapeutic challenges in cancer pain management: a systematic review of methadone.
    Journal of pain & palliative care pharmacotherapy, 2014, Volume: 28, Issue:3

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Pain Management

2014
Pharmacological options for the management of refractory cancer pain-what is the evidence?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:5

    Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; B

2015
Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence.
    Journal of pain and symptom management, 2015, Volume: 50, Issue:2

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Pain Management

2015
Methadone for cancer pain.
    The Cochrane database of systematic reviews, 2017, 02-08, Volume: 2

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Humans; Methadone; Middle Aged; Morphine; Neopla

2017
Equianalgesia: applying evidence-based practice guidelines.
    Clinical journal of oncology nursing, 2008, Volume: 12, Issue:3

    Topics: Analgesia; Analgesics, Opioid; Codeine; Drug Monitoring; Evidence-Based Medicine; Humans; Hydromorph

2008
Opioids in people with cancer-related pain.
    BMJ clinical evidence, 2008, Jul-31, Volume: 2008

    Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Codeine; Fentanyl; Humans; Methadone; Neoplasm

2008
Clinical approaches to special issues related to opioid therapy.
    Seminars in oncology nursing, 2009, Volume: 25, Issue:2 Suppl 1

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Nurse's Role; Nursing Assessment; Nursing Methodol

2009
The role of methadone in cancer pain treatment--a review.
    International journal of clinical practice, 2009, Volume: 63, Issue:7

    Topics: Analgesics, Opioid; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Hum

2009
[Opioid rotation: a therapeutic choice in the management of refractory cancer pain].
    Medicina clinica, 2010, Nov-06, Volume: 135, Issue:13

    Topics: Adult; Age Factors; Aged; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Hum

2010
Review of cancer pain management in patients receiving maintenance methadone therapy.
    The American journal of hospice & palliative care, 2011, Volume: 28, Issue:3

    Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Huma

2011
Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain?
    Palliative medicine, 2011, Volume: 25, Issue:5

    Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Humans; Methadone; Neoplasms; P

2011
The use of methadone for cancer pain.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:3

    Topics: Analgesics, Opioid; Attitude of Health Personnel; Biological Availability; Child; Clinical Protocols

2002
Intrathecal therapy for chronic pain.
    Stereotactic and functional neurosurgery, 2001, Volume: 77, Issue:1-4

    Topics: Administration, Oral; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Disease; Hum

2001
Morphine is not the only analgesic in palliative care: literature review.
    Journal of advanced nursing, 2004, Volume: 45, Issue:5

    Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Ketamine; Methadone; Morphine; Neoplasms; Pain; Pa

2004
Methadone for cancer pain.
    The Cochrane database of systematic reviews, 2004, Issue:2

    Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain; Pain Measurement; Randomized Contr

2004
Cancer pain management in children.
    Palliative medicine, 2004, Volume: 18, Issue:7

    Topics: Analgesics, Opioid; Anesthesia, Conduction; Child; Chronic Disease; Fentanyl; Humans; Injections, Sp

2004
Pain and terminal delirium research in the elderly.
    Clinics in geriatric medicine, 2005, Volume: 21, Issue:1

    Topics: Aged; Algorithms; Analgesics, Opioid; Anti-Infective Agents; Constipation; Delirium; Drug Interactio

2005
Difficult cases in pain management: use of methadone in a multifactorial approach.
    Clinical journal of oncology nursing, 2006, Volume: 10, Issue:1

    Topics: Administration, Oral; Aged; Analgesics, Opioid; Communication; Drug Monitoring; Female; Humans; Inte

2006
Methadone for treatment of cancer pain.
    Current oncology reports, 2006, Volume: 8, Issue:4

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain

2006
Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:10

    Topics: Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Routes; D

2007
Methadone for cancer pain.
    The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4

    Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain; Pain Measurement; Randomized Contr

2007
Methadone in the management of cancer pain: a review.
    Pain, 1993, Volume: 52, Issue:2

    Topics: Humans; Methadone; Neoplasms; Pain, Intractable

1993
Should people taking opioids for medical reasons be allowed to work and drive?
    Addiction (Abingdon, England), 1996, Volume: 91, Issue:11

    Topics: Accidents, Occupational; Accidents, Traffic; Analgesics, Opioid; Heroin Dependence; Humans; Long-Ter

1996
An update on the clinical use of methadone for cancer pain.
    Pain, 1997, Volume: 70, Issue:2-3

    Topics: Administration, Oral; Administration, Rectal; Analgesics, Opioid; Evaluation Studies as Topic; Human

1997
[Treatment of pain in oncology].
    Tumori, 1997, Volume: 83, Issue:2 Suppl

    Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl;

1997
Role of methadone in the management of pain in cancer patients.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:9

    Topics: Analgesics, Opioid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Male

1999
Opioid rotation for cancer pain: rationale and clinical aspects.
    Cancer, 1999, Nov-01, Volume: 86, Issue:9

    Topics: Analgesics, Opioid; Fentanyl; Humans; Hydromorphone; Methadone; Morphine; Narcotics; Neoplasms; Pain

1999
Opioid switch to oral methadone in cancer pain.
    Current opinion in oncology, 2000, Volume: 12, Issue:4

    Topics: Administration, Oral; Analgesics, Opioid; Combined Modality Therapy; Cross-Sectional Studies; Dose-R

2000
The rediscovery of methadone for cancer pain management.
    The Medical journal of Australia, 2000, Nov-20, Volume: 173, Issue:10

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain, Intractable; Prospective Studies

2000
Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:2

    Topics: Analgesics, Opioid; Drug Administration Routes; Drug Interactions; Humans; Methadone; Neoplasms; Pai

2001
[Treatment of pain in cancer with systemically administered opioids].
    Nederlands tijdschrift voor geneeskunde, 2001, May-19, Volume: 145, Issue:20

    Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Administration Schedule; Humans; Infusion Pump

2001
Strategies for the treatment of cancer pain in the new millennium.
    Drugs, 2001, Volume: 61, Issue:7

    Topics: Analgesics, Opioid; Cannabinoids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Human

2001
Methadone use in cancer patients with pain: a review.
    Journal of palliative medicine, 2002, Volume: 5, Issue:1

    Topics: Analgesics, Opioid; Drug Interactions; Humans; Methadone; Neoplasms; Pain

2002

Trials

36 trials available for methadone and Neoplasms

ArticleYear
Conversion ratios for opioid switching: a pragmatic study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Dec-29, Volume: 31, Issue:1

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Palliative Care

2022
Methadone versus morphine for postoperative pain in patients undergoing surgery for gynecological cancer: A randomized controlled clinical trial.
    Journal of clinical anesthesia, 2020, Volume: 61

    Topics: Analgesics, Opioid; Female; Humans; Methadone; Morphine; Neoplasms; Pain Measurement; Pain, Postoper

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain.
    The Clinical journal of pain, 2021, 09-01, Volume: 37, Issue:9

    Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Methadone; Morphine; Neoplasms

2021
Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?
    Clinical therapeutics, 2017, Volume: 39, Issue:9

    Topics: Aged; Analgesics, Opioid; Chromatography, High Pressure Liquid; Female; Humans; Male; Methadone; Mid

2017
Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.
    The oncologist, 2016, Volume: 21, Issue:8

    Topics: Aged; Ambulatory Care Facilities; Cancer Pain; Dose-Response Relationship, Drug; Female; Humans; Mal

2016
The role of methadone in opioid rotation-a Polish experience.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:5

    Topics: Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; M

2009
Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010, Volume: 18, Issue:2

    Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opi

2010
The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
    Journal of palliative medicine, 2010, Volume: 13, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Electrocardiog

2010
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:3

    Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Tole

2011
How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:16

    Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug;

2011
Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:8

    Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans;

2012
Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone.
    British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2

    Topics: Adult; Aged; Analgesia, Epidural; Dexamethasone; Drug Administration Routes; Female; Humans; Lidocai

2013
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation

2004
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation

2004
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation

2004
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation

2004
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Cancer, 2004, Dec-15, Volume: 101, Issue:12

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Drug Administratio

2004
Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study.
    Journal of pain and symptom management, 2004, Volume: 28, Issue:6

    Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Female;

2004
Rapid switching between transdermal fentanyl and methadone in cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Methadone; Middle Age

2005
Intermittent subcutaneous methadone administration in the management of cancer pain.
    Journal of pain & palliative care pharmacotherapy, 2005, Volume: 19, Issue:2

    Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Injec

2005
Methadone in the treatment of pain and terminal delirum in advanced cancer patients.
    Palliative & supportive care, 2005, Volume: 3, Issue:4

    Topics: Aged; Analgesics, Opioid; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule;

2005
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    European journal of pain (London, England), 2008, Volume: 12, Issue:8

    Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Analgesics, Opi

2008
Combination therapy with ibuprofen and methadone for chronic cancer pain.
    The American journal of medicine, 1984, Jul-13, Volume: 77, Issue:1A

    Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Emotions; Fem

1984
Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine.
    Journal of clinical pharmacology, 1983, Volume: 23, Issue:1

    Topics: Adult; Analgesics; Biological Availability; Female; Humans; Injections, Intramuscular; Male; Methado

1983
Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain.
    Pain, 1995, Volume: 62, Issue:2

    Topics: Aged; Analgesics, Opioid; Capsules; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female;

1995
Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Administration, Oral; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Dose-Response Relatio

1996
Opioid-sparing effect of diclofenac in cancer pain.
    Journal of pain and symptom management, 1997, Volume: 14, Issue:1

    Topics: Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Di

1997
Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Adult; Aged; Analgesics, Opioid; Female; Home Care Services; Humans; Male; Methadone; Middle Aged; M

1998
Diclofenac does not modify methadone bioavailability in cancer patients.
    Journal of pain and symptom management, 1999, Volume: 17, Issue:4

    Topics: Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Diclofen

1999
Methadone titration in opioid-resistant cancer pain.
    European journal of cancer care, 1999, Volume: 8, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Administration Schedu

1999
Methadone response in advanced cancer patients with pain followed at home.
    Journal of pain and symptom management, 1999, Volume: 18, Issue:3

    Topics: Analgesics, Opioid; Female; Home Care Services; Humans; Male; Methadone; Middle Aged; Neoplasms; Pai

1999
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-01, Volume: 19, Issue:11

    Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad

2001
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-01, Volume: 19, Issue:11

    Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad

2001
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-01, Volume: 19, Issue:11

    Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad

2001
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-01, Volume: 19, Issue:11

    Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad

2001
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain.
    Pain, 2002, Volume: 96, Issue:3

    Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Hydromorphone; Levorphanol; Male; Methado

2002
Pain relief for cancer patients.
    The American journal of nursing, 1978, Volume: 78, Issue:12

    Topics: Chloroform; Clinical Trials as Topic; Cocaine; Dextrothyroxine; Drug Combinations; Drug Evaluation;

1978
Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain.
    Clinical pharmacology and therapeutics, 1990, Volume: 47, Issue:5

    Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Infusions,

1990
Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study.
    Pain, 1989, Volume: 38, Issue:2

    Topics: Adult; Aged; Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inje

1989
A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer.
    Pain, 1986, Volume: 25, Issue:3

    Topics: Administration, Oral; Aged; Biological Availability; Clinical Trials as Topic; Dose-Response Relatio

1986
A randomized study on oral administration of morphine and methadone in the treatment of cancer pain.
    Journal of pain and symptom management, 1986,Fall, Volume: 1, Issue:4

    Topics: Administration, Oral; Clinical Trials as Topic; Female; Humans; Male; Methadone; Morphine; Neoplasms

1986

Other Studies

144 other studies available for methadone and Neoplasms

ArticleYear
Pharmacogenetics of Methadone for Pain Management in Palliative Care.
    Journal of pain and symptom management, 2022, Volume: 63, Issue:1

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Neoplasms; Pain Management; Palliative Care; Pha

2022
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
    Biological & pharmaceutical bulletin, 2021, Volume: 44, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F

2021
Association of polymorphisms in
    Pharmacogenomics, 2022, Volume: 23, Issue:5

    Topics: Analgesics, Opioid; beta-Arrestin 2; Cancer Pain; Humans; Methadone; Neoplasms; Pain; Polymorphism,

2022
Methadone as First-line Opioid for the Management of Cancer Pain.
    The oncologist, 2022, 04-05, Volume: 27, Issue:4

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Neoplasms; Pain; Prospective Studies

2022
Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.
    JAMA oncology, 2022, 08-01, Volume: 8, Issue:8

    Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Cancer Pain; Consensus; Female; Humans; Male; Me

2022
Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.
    Scientific reports, 2022, 10-19, Volume: 12, Issue:1

    Topics: Adult; Analgesics, Opioid; Chronic Pain; Death; G Protein-Coupled Inwardly-Rectifying Potassium Chan

2022
Methadone switching for refractory cancer pain.
    BMC palliative care, 2022, Nov-02, Volume: 21, Issue:1

    Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Humans; Methadone; Neoplasms; Retrospective Stud

2022
Two Patients Experience Same-Day Analgesic Effect of Methadone on Trigeminal Neuralgia Secondary to Malignancy: A Case Report.
    Journal of palliative medicine, 2023, Volume: 26, Issue:7

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Quality of Life; Treatment Outcome; Trigeminal Neu

2023
Switching to Intravenous Methadone in Advanced Cancer Patients: A Retrospective Analysis.
    Journal of pain and symptom management, 2023, Volume: 66, Issue:4

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Retrospective Studies

2023
[Drug therapy for cancer-related pain-evidence regarding hydromorphone, oxycodone, and methadone : Presentation and summary of three Cochrane reviews].
    Urologie (Heidelberg, Germany), 2023, Volume: 62, Issue:6

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Hydromorphone; Methadone; Neoplasms; Oxycodone

2023
A better interpretation of data regarding the opioid switching to methadone.
    BMC palliative care, 2023, Jun-07, Volume: 22, Issue:1

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain Measurement; Palliative Care

2023
Reply to "A better interpretation of data regarding the opioid switching to methadone".
    BMC palliative care, 2023, Jun-07, Volume: 22, Issue:1

    Topics: Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Humans; Methadone; Neoplasms; Pai

2023
Juggling Two Full-Time Jobs - Methadone Clinic Engagement and Cancer Care.
    The New England journal of medicine, 2023, Nov-30, Volume: 389, Issue:22

    Topics: Humans; Methadone; Neoplasms; Opiate Substitution Treatment; Opioid-Related Disorders

2023
The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care.
    Journal of palliative medicine, 2020, Volume: 23, Issue:2

    Topics: Analgesics, Opioid; Cancer Pain; Death; Humans; Methadone; Neoplasms; Palliative Care; Sweden

2020
Methadone rotation for cancer pain: an observational study.
    BMJ supportive & palliative care, 2022, Volume: 12, Issue:e6

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Morphine; Neoplasms; Neuralgia

2022
The role of methadone in cancer-induced bone pain: a retrospective cohort study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:3

    Topics: Aged; Analgesics, Opioid; Bone and Bones; Cancer Pain; Female; Humans; Male; Methadone; Neoplasms; P

2021
Methadone for Cancer Pain in Pediatric End-of-Life Care.
    The American journal of hospice & palliative care, 2021, Volume: 38, Issue:8

    Topics: Analgesics, Opioid; Cancer Pain; Child; Drug Tolerance; Humans; Methadone; Neoplasms; Retrospective

2021
A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children.
    Drug and alcohol dependence, 2021, 02-01, Volume: 219

    Topics: Adolescent; Aftercare; Analgesics, Opioid; Child; Child, Preschool; Female; Hospitalization; Humans;

2021
Combination therapy with methadone and duloxetine for cancer-related pain: a retrospective study.
    Annals of palliative medicine, 2021, Volume: 10, Issue:3

    Topics: Cancer Pain; Duloxetine Hydrochloride; Humans; Methadone; Neoplasms; Retrospective Studies; Treatmen

2021
First-line methadone for cancer pain: titration time analysis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:11

    Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Dose-Response Relationship, Drug; Humans; Methad

2021
Antinociceptive synergism upon the joint use of methadone and Phα1β in a model of cancer-related pain in C57BL/6J mice.
    Life sciences, 2021, Aug-01, Volume: 278

    Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Cancer Pain; Dr

2021
Assistance of a Palliative Care Certified Nurse in the Alleviation of Refractory Cancer Pain by Switching Opioids to Oral Methadone in a Japanese Outpatient Setting.
    Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association, 2021, 12-01, Volume: 23, Issue:6

    Topics: Analgesics, Opioid; Cancer Pain; Humans; Japan; Methadone; Neoplasms; Outpatients; Pain, Intractable

2021
The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain.
    Pediatric blood & cancer, 2017, Volume: 64, Issue:11

    Topics: Adolescent; Adult; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Dose-Response Relations

2017
Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report.
    Journal of palliative medicine, 2017, Volume: 20, Issue:9

    Topics: Analgesics, Opioid; Humans; Male; Methadone; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Pain;

2017
Response to the Article "Overall Survival among Cancer Patients Undergoing Opioid Rotation to Methadone Compared to Other Opioids".
    Journal of palliative medicine, 2017, Volume: 20, Issue:11

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain Management; Rotation

2017
Intravenous methadone in a patient with advanced cancer.
    BMJ supportive & palliative care, 2019, Volume: 9, Issue:3

    Topics: Administration, Intravenous; Analgesics, Opioid; Cancer Pain; Humans; Male; Methadone; Middle Aged;

2019
Evaluation of QTc Interval Prolongation Among Patients With Cancer Using Enteral Methadone.
    The American journal of hospice & palliative care, 2019, Volume: 36, Issue:3

    Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Female; Humans; Long

2019
Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.
    Paediatric drugs, 2019, Volume: 21, Issue:2

    Topics: Adult; Algorithms; Analgesics; Child; Chronic Pain; Clinical Decision-Making; Humans; Ketamine; Medi

2019
QT Interval Prolongation in the Pediatric Oncologic Population on Methadone.
    Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:2

    Topics: Adolescent; Adult; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Female; Follow-Up Studi

2020
Dying To Access Methadone.
    Health affairs (Project Hope), 2019, Volume: 38, Issue:7

    Topics: Adult; Analgesics, Opioid; Government Regulation; Heroin Dependence; Hospice Care; Humans; Male; Met

2019
Changes of QTc interval after opioid switching to oral methadone.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:12

    Topics: Aged; Analgesics, Opioid; Electrocardiography; Female; Humans; Linear Models; Long QT Syndrome; Male

2013
Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study.
    Journal of palliative medicine, 2013, Volume: 16, Issue:11

    Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle

2013
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:3

    Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Breakthrough Pain; Constipation; Female; Fentanyl;

2014
What is your gut feeling about opioid rotation?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-20, Volume: 33, Issue:3

    Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Biological Availability; Delaye

2015
Extreme doses of intravenous methadone for severe pain in two children with cancer.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:6

    Topics: Adolescent; Analgesics, Opioid; Child; Female; Humans; Injections, Intravenous; Male; Methadone; Neo

2015
Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:8

    Topics: Analgesics, Opioid; Cancer Pain; Developing Countries; Female; Humans; Male; Methadone; Middle Aged;

2016
Methadone as a Coanalgesic for Palliative Care Cancer Patients.
    Journal of palliative medicine, 2016, Volume: 19, Issue:9

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Palliative Care

2016
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 68

    Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neoplasms; Neuralgia; Pain

2016
Overall Survival among Cancer Patients Undergoing Opioid Rotation to Methadone Compared to Other Opioids.
    Journal of palliative medicine, 2017, Volume: 20, Issue:6

    Topics: Analgesics, Opioid; Female; Humans; Kaplan-Meier Estimate; Male; Methadone; Middle Aged; Neoplasms;

2017
[Use of methadone for support of oncological treatment? : Statement of the working group on tumor pain of the German Pain Society].
    Schmerz (Berlin, Germany), 2017, Volume: 31, Issue:1

    Topics: Analgesics, Opioid; Antineoplastic Agents; Brain Neoplasms; Cancer Pain; Drug Approval; Drug Resista

2017
Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case-Control Study.
    Journal of palliative medicine, 2017, Volume: 20, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Case-Control Studies; Dose-Response

2017
Opioid-induced pain.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

    Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans;

2008
Myoclonus associated with high-dose parenteral methadone.
    Journal of palliative medicine, 2008, Volume: 11, Issue:6

    Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Hospice Care; Humans; Male; Methadone;

2008
[Analgesics and palliative care].
    Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4

    Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pain; Palliative C

2008
Switching from methadone to a different opioid: what is the equianalgesic dose ratio?
    Journal of palliative medicine, 2008, Volume: 11, Issue:8

    Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle

2008
Conversion from parenteral to oral methadone.
    Journal of pain & palliative care pharmacotherapy, 2008, Volume: 22, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Biological Availability; Dose-Res

2008
Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
    Journal of pain and symptom management, 2009, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cohort Studies; Dose-Response Relationship, Drug

2009
Cauda equina syndrome and decreasing opioid requirements.
    Journal of pain and symptom management, 2009, Volume: 37, Issue:4

    Topics: Analgesics, Opioid; Humans; Methadone; Narcotic Antagonists; Neoplasms; Polyradiculopathy; Receptors

2009
Methadone initiation and rotation in the outpatient setting for patients with cancer pain.
    Cancer, 2010, Jan-15, Volume: 116, Issue:2

    Topics: Ambulatory Care; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methadone;

2010
Recent advances in the treatment of cancer pain.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:4

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain, Intractable; Palliative Care

2010
The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
    Journal of palliative medicine, 2010, Volume: 13, Issue:6

    Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Long QT Syndrome; M

2010
A formal feasibility study of sublingual methadone for breakthrough cancer pain.
    Palliative medicine, 2010, Volume: 24, Issue:7

    Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Alberta; Analgesics, Opioid; Drug Monito

2010
Neostigmine for the treatment of gastrointestinal atony: a report of one case.
    Journal of palliative medicine, 2011, Volume: 14, Issue:11

    Topics: Aged; Analgesics, Opioid; Constipation; Female; Humans; Injections, Subcutaneous; Methadone; Neoplas

2011
Methadone maintenance and cancer risk: an Israeli case registry study.
    Drug and alcohol dependence, 2011, Dec-01, Volume: 119, Issue:1-2

    Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Cohort Studies; Databases, Factual; Female; Humans; Isr

2011
Switching from oxycodone to methadone in advanced cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:1

    Topics: Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle

2012
Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
    Journal of pain & palliative care pharmacotherapy, 2008, Volume: 22, Issue:4

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Opioid; Delayed-Action Preparati

2008
Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Substitut

2012
Stop and go strategy for opioid switching requires flexibility.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:6

    Topics: Analgesics, Opioid; Drug Substitution; Female; Humans; Male; Methadone; Morphine; Neoplasms; Oxycodo

2012
Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.
    Pain medicine (Malden, Mass.), 2012, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Ne

2012
Switching from methadone to tapentadol for cancer pain.
    Journal of pain and symptom management, 2012, Volume: 44, Issue:3

    Topics: Aged; Analgesics, Opioid; Female; Humans; Methadone; Multiple Myeloma; Neoplasms; Pain; Phenols; Tap

2012
Three weeks from diagnosis to death: the chaotic journey of a long-term methadone maintenance patient with terminal cancer.
    Journal of pain and symptom management, 2013, Volume: 46, Issue:4

    Topics: Australia; Fatal Outcome; Humans; Male; Methadone; Middle Aged; Neoplasms; Opioid-Related Disorders;

2013
Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series.
    Journal of palliative medicine, 2013, Volume: 16, Issue:3

    Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Neoplasms

2013
Opioid "holiday" following antagonist supported detoxification during general anesthesia improves opioid agonist response in a cancer patient with opioid addiction.
    Anesthesiology, 2003, Volume: 98, Issue:2

    Topics: Analgesia, Epidural; Analgesics, Opioid; Anesthesia, General; Anesthetics, Local; Bone Neoplasms; Bu

2003
Opioid plasma concentration during switching from morphine to methadone: preliminary data.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003, Volume: 11, Issue:5

    Topics: Administration, Oral; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administratio

2003
An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population.
    Palliative medicine, 2003, Volume: 17, Issue:2

    Topics: Administration, Oral; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; China; Drug Ad

2003
Methadone and the hospice patient: prescribing trends in the home-care setting.
    Pain medicine (Malden, Mass.), 2003, Volume: 4, Issue:3

    Topics: Analgesics, Opioid; Drug Prescriptions; Drug Utilization; Female; Home Care Services; Hospice Care;

2003
A CLINICAL TRIAL OF A MIXTURE OF LEVORPHANOL AND LEVALLORPHAN AS AN ORAL ANALEGESIC.
    British journal of anaesthesia, 1964, Volume: 36

    Topics: Drug Therapy; Humans; Levallorphan; Levorphanol; Methadone; Neoplasms; Osteoarthritis; Pain; Substan

1964
Switching to methadone: 'ad libitum' or fixed dose ratio?
    Palliative medicine, 2004, Volume: 18, Issue:1

    Topics: Analgesics, Opioid; Chronic Disease; Humans; Methadone; Morphine; Neoplasms; Pain; Patient Satisfact

2004
Methadone: an orphan drug?
    Journal of palliative medicine, 2004, Volume: 7, Issue:1

    Topics: Analgesics, Opioid; Fees, Pharmaceutical; Humans; Methadone; Neoplasms; Orphan Drug Production; Pain

2004
Oral methadone for cancer pain: no indication of Q-T interval prolongation or torsades de pointes.
    Journal of pain and symptom management, 2004, Volume: 28, Issue:4

    Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Electrocardiography; Heart Rate; Humans; Methadone; Neopla

2004
Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Journal of pain & palliative care pharmacotherapy, 2005, Volume: 19, Issue:2

    Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Hydromorphone; Methadone; Midd

2005
Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain.
    Therapeutic drug monitoring, 2006, Volume: 28, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chromatography, High Pressure Liquid; Female; Ha

2006
Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study.
    Journal of palliative medicine, 2007, Volume: 10, Issue:2

    Topics: Administration, Sublingual; Aged; Alberta; Analgesics, Opioid; Clinical Protocols; Drug Monitoring;

2007
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
    Journal of palliative medicine, 2007, Volume: 10, Issue:2

    Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Drug Administration Schedule; Female; Fe

2007
Subcutaneous methadone--an issue revisited.
    Journal of pain and symptom management, 2007, Volume: 34, Issue:6

    Topics: Aged; Analgesics, Opioid; Humans; Injections, Subcutaneous; Low Back Pain; Male; Methadone; Middle A

2007
Methadone analgesia for children with advanced cancer.
    Pediatric blood & cancer, 2008, Volume: 51, Issue:3

    Topics: Adolescent; Analgesia; Analgesics, Opioid; Child; Child, Preschool; Drug Evaluation; Drug-Related Si

2008
Pharmaceutics: choice of a strong analgesic for cancer patients.
    Cancer nursing, 1982, Volume: 5, Issue:1

    Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain, Intractable

1982
Patient-controlled dose regimen of methadone for chronic cancer pain.
    British medical journal (Clinical research ed.), 1981, Mar-07, Volume: 282, Issue:6266

    Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Female; Humans; Male; Methadone; Middle

1981
[Peroral analgetic treatment with a methadone mixture in terminal cancer patients].
    Ugeskrift for laeger, 1981, Jun-15, Volume: 143, Issue:25

    Topics: Administration, Oral; Aged; Female; Humans; Male; Methadone; Middle Aged; Neoplasms; Pain; Palliativ

1981
[Long-lasting pain relief with rectal methadone therapy].
    Lakartidningen, 1983, Jan-19, Volume: 80, Issue:3

    Topics: Aged; Female; Humans; Male; Methadone; Neoplasms; Pain; Palliative Care; Rectum; Suppositories

1983
Methadone and intravenous morphine requirements. Treatment of pain due to advanced cancer.
    New York state journal of medicine, 1983, Volume: 83, Issue:7

    Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain, In

1983
Pharmacist intervention in methadone administration to cancer patients with chronic pain.
    American journal of hospital pharmacy, 1983, Volume: 40, Issue:9

    Topics: Adolescent; Adult; Aged; Chronic Disease; Humans; Methadone; Middle Aged; Neoplasms; Pain; Pharmacis

1983
Patient-controlled dose regimen of methadone for chronic cancer pain.
    British medical journal (Clinical research ed.), 1981, Apr-25, Volume: 282, Issue:6273

    Topics: Analgesics; Humans; Methadone; Neoplasms

1981
[Morphine and methadone in severe cancer pain--new pharmacokinetic bases for optimal therapy].
    Pharmaceutica acta Helvetiae, 1983, Volume: 58, Issue:7

    Topics: Chronic Disease; Humans; Kinetics; Methadone; Morphine; Neoplasms; Pain

1983
Methadone for pain relief in disseminated malignant disease.
    Oncology nursing forum, 1980,Spring, Volume: 7, Issue:2

    Topics: Female; Humans; Male; Methadone; Neoplasm Metastasis; Neoplasms; Pain, Intractable; Terminal Care

1980
How to use methadone. A handbook for patients and families.
    Oncology nursing forum, 1981,Winter, Volume: 8, Issue:1

    Topics: Humans; Methadone; Neoplasms; Pain; Patient Education as Topic; Self Administration

1981
How to use methadone for the cancer patient's pain.
    The American journal of nursing, 1980, Volume: 80, Issue:9

    Topics: Dose-Response Relationship, Drug; Humans; Methadone; Neoplasms; Pain, Intractable

1980
Nursing care in childhood cancer: methadone.
    The American journal of nursing, 1982, Volume: 82, Issue:3

    Topics: Adolescent; Analgesics; Child; Child, Preschool; Humans; Infant; Liver; Methadone; Neoplasms; Pain,

1982
Clinical evaluation of oral methadone in treatment of cancer pain.
    Acta anaesthesiologica Scandinavica. Supplementum, 1982, Volume: 74

    Topics: Administration, Oral; Adult; Aged; Female; Half-Life; Humans; Male; Methadone; Middle Aged; Neoplasm

1982
Clinical evaluation of combined treatment with methadone and psychotropic drugs in cancer patients.
    Acta anaesthesiologica Scandinavica. Supplementum, 1982, Volume: 74

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Methadone; Middle Aged; M

1982
Pharmacokinetic basis for optimal methadone treatment of pain in cancer patients.
    Acta anaesthesiologica Scandinavica. Supplementum, 1982, Volume: 74

    Topics: Adult; Aged; Female; Half-Life; Humans; Kinetics; Male; Methadone; Middle Aged; Models, Biological;

1982
Oral methadone for relief of chronic pain from cancer.
    The New England journal of medicine, 1982, Apr-22, Volume: 306, Issue:16

    Topics: Chronic Disease; Humans; Methadone; Morphine; Neoplasms; Pain, Intractable

1982
Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein.
    Clinical pharmacology and therapeutics, 1982, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methadone; Middle Aged; Neoplasms; Orosomucoid; Serum

1982
Experience with dipipanone elixir in the management of cancer related pain--case study.
    Palliative medicine, 1994, Volume: 8, Issue:1

    Topics: Aged; Aged, 80 and over; Analgesics; Dosage Forms; Female; Humans; Male; Methadone; Middle Aged; Neo

1994
Successful use of methadone in nociceptive cancer pain unresponsive to morphine.
    Palliative medicine, 1994, Volume: 8, Issue:2

    Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Methado

1994
Respiratory depression in a patient receiving oral methadone for cancer pain.
    Journal of pain and symptom management, 1995, Volume: 10, Issue:5

    Topics: Administration, Oral; Female; Humans; Methadone; Middle Aged; Neoplasms; Pain; Respiration Disorders

1995
Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adolescent; Adult; Analgesics; Child; Drug Tolerance; Female; Humans; Male; Methadone; Middle Aged;

1993
Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists.
    Pain, 1994, Volume: 59, Issue:2

    Topics: Adult; Aged; Analgesics, Opioid; Child; Delayed-Action Preparations; Female; Humans; Hyperalgesia; M

1994
CSF neuropeptides in cancer pain: effects of spinal opioid therapy.
    Acta anaesthesiologica Scandinavica, 1993, Volume: 37, Issue:5

    Topics: Aged; Bupivacaine; Female; Humans; Injections, Epidural; Injections, Spinal; Male; Methadone; Middle

1993
Methadone for treatment of cancer pain.
    JAMA, 1996, Feb-21, Volume: 275, Issue:7

    Topics: Analgesics, Opioid; Drug and Narcotic Control; Humans; Methadone; Neoplasms; Pain, Intractable

1996
Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations.
    Cancer treatment reviews, 1996, Volume: 22 Suppl A

    Topics: Adult; Aged; Analgesics, Opioid; Capsules; Female; Humans; Male; Methadone; Middle Aged; Neoplasms;

1996
Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
    Cancer, 1996, Aug-15, Volume: 78, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Cohort Studies; Dose-Response Rel

1996
Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10

    Topics: Administration, Oral; Aged; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Neopla

1996
Pharmacologic treatment of cancer pain.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain; Therapeutic Equivalency

1997
Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine.
    Pain, 1997, Volume: 73, Issue:2

    Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Dose-Response Relationship, Drug; Humans; Infusio

1997
Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.
    Cancer, 1998, Mar-15, Volume: 82, Issue:6

    Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Admini

1998
Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug;

1998
Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer.
    BMJ (Clinical research ed.), 1998, Jul-04, Volume: 317, Issue:7150

    Topics: Analgesics, Opioid; Anesthetics, Dissociative; Humans; Ketamine; Methadone; N-Methylaspartate; Neopl

1998
Comment on Manfredi et al.,Pain, 70 (1997) 199-101.
    Pain, 1998, Volume: 77, Issue:1

    Topics: Analgesics, Opioid; Humans; Hydromorphone; Injections, Intravenous; Methadone; Morphine; Neoplasms;

1998
Methadone in cancer pain management: individualize dose and titrate to effect.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain Management

1998
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re

1998
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re

1998
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re

1998
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re

1998
Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases.
    The Clinical journal of pain, 1998, Volume: 14, Issue:4

    Topics: Administration, Oral; Analgesia, Patient-Controlled; Analgesics, Opioid; Burns; Child; Child, Presch

1998
Opioid substitution to reduce adverse effects in cancer pain management.
    The Medical journal of Australia, 1999, Jan-18, Volume: 170, Issue:2

    Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hospice Care; Humans; Male; Medical A

1999
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans;

1999
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans;

1999
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans;

1999
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans;

1999
Methadone: outpatient titration and monitoring strategies in cancer patients.
    Journal of pain and symptom management, 1999, Volume: 18, Issue:5

    Topics: Analgesics, Opioid; Cohort Studies; Humans; Methadone; Monitoring, Physiologic; Neoplasms; Outpatien

1999
Pain management in patients with advanced cancer.
    Annals of internal medicine, 2000, Apr-04, Volume: 132, Issue:7

    Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain

2000
Respiratory depression during methadone rotation in a patient with advanced cancer.
    Journal of palliative care, 2000,Summer, Volume: 16, Issue:2

    Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Humans; Lung Neoplasms; Male; Methadone; Neoplasms; Pai

2000
[Treating hospitalized children in severe pain with oral methadone].
    Harefuah, 1998, Mar-15, Volume: 134, Issue:6

    Topics: Administration, Oral; Analgesics, Opioid; Burns; Child; Child, Hospitalized; Child, Preschool; Femal

1998
The merits of methadone.
    The American journal of nursing, 2000, Volume: 100, Issue:7

    Topics: Adult; Analgesics, Opioid; Child; Child, Preschool; Chronic Disease; Humans; Methadone; Morphine; Ne

2000
Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy.
    Journal of pain and symptom management, 2001, Volume: 21, Issue:2

    Topics: Adult; Analgesia; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methadone;

2001
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
    British journal of cancer, 2001, Mar-02, Volume: 84, Issue:5

    Topics: Administration, Oral; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Administration Schedule; F

2001
The rediscovery of methadone for cancer pain management.
    The Medical journal of Australia, 2001, May-21, Volume: 174, Issue:10

    Topics: Humans; Methadone; Neoplasms; Pain, Intractable

2001
Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
    Cancer, 2001, Oct-01, Volume: 92, Issue:7

    Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Drug Administration Schedule; Female

2001
Methadone: the question or the answer for US opioid therapy and pharmaco-economics?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:8

    Topics: Analgesics, Opioid; Humans; Methadone; Models, Theoretical; Neoplasms; Opioid-Related Disorders; Pai

2001
Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine.
    Journal of pain and symptom management, 2002, Volume: 23, Issue:1

    Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Child; Humans; Infusions, Intravenous; Male; Meth

2002
[Strong opiate analgesics for cancer pain].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1979, Jul-10, Volume: 99, Issue:19-21

    Topics: Humans; Methadone; Morphine; Narcotics; Neoplasms; Palliative Care

1979
Cancer patients dying at home. The last 24 hours.
    The Practitioner, 1979, Volume: 223, Issue:1338

    Topics: Attitude to Death; Death; Home Care Services; Humans; Methadone; Methotrimeprazine; Neoplasms; Palli

1979
Important clinical pharmacologic considerations in the use of methadone in cancer patients.
    Cancer treatment reports, 1979, Volume: 63, Issue:3

    Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Male; Methadone; Middle Aged; Neoplasms;

1979
Death rates and causes of death among opioid addicts in community drug treatment programs during 1970-1973.
    The American journal of drug and alcohol abuse, 1975, Volume: 2, Issue:1

    Topics: Adult; Age Factors; Black or African American; Cardiovascular Diseases; Community Mental Health Serv

1975
Population-based study of malignancies and HIV infection among injecting drug users in a New York City methadone treatment program, 1985-1991.
    AIDS (London, England), 1992, Volume: 6, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Female; HIV Infections; Humans; Incidence; Male; Me

1992
Continuous epidural methadone treatment for cancer pain.
    The Clinical journal of pain, 1991, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Chronic Disease; Female; Humans; Ma

1991
Treatment of severe cancer pain by continuous infusion of subcutaneous opioids.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1991, Volume: 121

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Methadone; Middle A

1991
Local toxicity with subcutaneous methadone. Experience of two centers.
    Pain, 1991, Volume: 45, Issue:2

    Topics: Adult; Erythema; Female; Humans; Injections, Subcutaneous; Male; Methadone; Middle Aged; Neoplasms;

1991
Epidural and intrathecal opiates: cerebrospinal fluid and plasma profiles in patients with chronic cancer pain.
    Clinical pharmacology and therapeutics, 1985, Volume: 38, Issue:6

    Topics: Adult; Aged; beta-Endorphin; Drug Evaluation; Endorphins; Epidural Space; Female; Half-Life; Humans;

1985
I.v. infusion of opioids for cancer pain: clinical review and guidelines for use.
    Cancer treatment reports, 1986, Volume: 70, Issue:5

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Hum

1986
Exceptionally high narcotic analgesic requirements in a terminally ill cancer patient.
    Clinical pharmacy, 1986, Volume: 5, Issue:10

    Topics: Adult; Analgesics, Opioid; Combined Modality Therapy; Drug Tolerance; Female; Humans; Hydromorphone;

1986
In vivo carcinogenesis assay of L-alpha-acetylmethadol.HCl in rodents.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1988, Volume: 11, Issue:4

    Topics: Animals; Carcinogenicity Tests; Eating; Female; Lethal Dose 50; Male; Methadone; Methadyl Acetate; M

1988
In vivo carcinogenesis assay of DL-methadone.HCl in rodents.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1988, Volume: 11, Issue:4

    Topics: Animals; Body Weight; Carcinogenicity Tests; Eating; Female; Lethal Dose 50; Male; Methadone; Mice;

1988
[3-step pharmacologic treatment of pain in cancer. Preliminary experience in Chile].
    Revista medica de Chile, 1988, Volume: 116, Issue:5

    Topics: Acetaminophen; Adult; Analgesics; Chile; Codeine; Drug Administration Schedule; Female; Follow-Up St

1988
Estimation of methadone clearance: application in the management of cancer pain.
    Pain, 1988, Volume: 33, Issue:3

    Topics: Blood Specimen Collection; Forecasting; Humans; Methadone; Models, Biological; Neoplasms; Pain Manag

1988
Cancer pain control with a combination of methadone, amitriptyline, and non-narcotic analgesic therapy: a case series analysis.
    Journal of pain and symptom management, 1987,Spring, Volume: 2, Issue:2

    Topics: Adolescent; Adult; Aged; Amitriptyline; Analgesics; Drug Therapy, Combination; Female; Humans; Male;

1987
Surgical management of pain in cancer of the head and neck.
    The Surgical clinics of North America, 1973, Volume: 53, Issue:1

    Topics: Alcohols; Autonomic Nerve Block; Carbamazepine; Chlorpromazine; Cranial Nerves; Gastrostomy; Head; H

1973
A gas-liquid chromatographic method for the quantitative determination of methadone in human plasma and urine.
    Journal of chromatography, 1972, Feb-23, Volume: 65, Issue:2

    Topics: Chromatography, Gas; Humans; Methadone; Methods; Neoplasms; Pain; Time Factors

1972
A look at narcotic and nonnarcotic analgesics.
    Postgraduate medicine, 1971, Volume: 49, Issue:6

    Topics: Analgesics; Dextropropoxyphene; Drug Antagonism; Drug Combinations; Drug Prescriptions; Drug Toleran

1971